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ABSTRACT 
Characterization of Beryllium as a Novel Agent to Study Cell Cycle Arrest 
and Cellular Senescence 
 
By 
Priyatham Gorjala 
 
Dr. Ronald K. Gary, Examination Committee Chair 
Associate Professor, Biochemistry 
Department of Chemistry 
University of Nevada, Las Vegas 
 
Cancer cells evade senescence, apoptosis, and other constraints on 
proliferation, often via mutation of the p53 tumor suppressor gene (TP53).  Normal 
human lung fibroblasts have been shown to enter premature senescence upon exposure 
to beryllium. In these cells, BeSO4 stabilizes p53 protein, increases p21 gene 
expression, induces senescence-associated β-galactosidase activity and causes cell 
proliferation arrest. In the present study, we have investigated whether BeSO4 is able to 
induce similar effects in cancer cells that have wildtype p53. We have demonstrated that 
beryllium salt at low concentration can induce molecular changes in the p53 signaling 
pathway leading to cell cycle arrest in beryllium-sensitive cancer cells. The p53 
transcription factor is the central regulator of the mammalian DNA damage response.  
However, unlike most agents that activate p53, beryllium did not cause DNA damage.  
We have discovered that the growth arresting effects of beryllium are mediated through 
the p53-dependent p21 pathway. We have also found that BeSO4 may be influencing the 
regulation of cyclin E2, a cyclin that controls passage of cells from G1 to S phase of the 
iv 
 
cell cycle. Increased caspase 3/7 activity was also seen in response to BeSO4 treatment. 
However, the number of cells undergoing apoptosis was not proportional to the activity 
of caspase 3/7, suggesting that the beryllium response is primarily cytostatic rather than 
apoptotic. These observations indicate that beryllium suppresses cell proliferation 
through a senescence-related p53 signaling pathway that  differs from the DNA damage 
response pathway. These unusual properties make beryllium salt a potent tool to 
investigate p53-mediated growth control pathways in both normal and cancerous cell 
types. 
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CHAPTER 1  INTRODUCTION 
PURPOSE OF STUDY 
Beryllium (Be2+) is a divalent cation that has the ability to inhibit growth of various 
cell lines. The exact mechanism of action as to how beryllium causes cell cycle arrest or 
shows anti-proliferative effect is not clearly understood. It has been demonstrated that 
Be2+ in extremely low doses over short duration increases p21 mRNA and in long 
exposures can induce expression of senescence-associated β-galactosidase activity in 
Human fibroblasts (HFL-1) (Coates et al., 2007). The aim of this study is to improve our 
understanding of the mechanism of action of beryllium salt as a cytostatic agent. 
• Chapter 3 presents the results of a survey on the effect of beryllium on various 
cancer cell lines and identifies a beryllium sensitive and a resistant cell line for further 
study. 
• Chapter 4 covers the data from a study that was done to evaluate the effect of 
beryllium on susceptible cancer cell line. Beryllium was found to be able to induce 
senescence-like cell cycle arrest through a pathway that may be different from DNA 
damage pathway. 
• Chapter 5 includes data that demonstrates p53 dependence of the effects of 
beryllium especially p21 increase and cell cycle arrest. The experiments were done 
using A172 cell line (human glioblastoma) with p53 expression or function knocked 
down using 3 different techniques (i.e., siRNA, shRNA and E6 protein expression.) 
• Chapter 6 documents the results of experiments done to analyze the level of 
caspase 3/7 activation and to verify if the activation of caspase 3/7 results in 
apoptosis. 
2 
RESEARCH QUESTIONS 
Beryllium can induce growth arrest in different types of cell lines. The existing 
evidence indicates that it may be using p53-p21 pathway to achieve this. In this thesis 
we have attempted to answer the following research questions: 
1. Research question 1: Does beryllium induce growth arrest equally in various cell 
types? 
Test: Survey 12 cell lines exposed  to eight different  concentrations of beryllium 
ranging from 0-1000µM over a period of 5 days and count the total number of attached 
cells present at the end of growth period using Cy-Quant assay. 
2. Research question 2: Does beryllium dosing induce expression of p21 and 
senescence in cancer cell lines similar to HFL-1 cells? 
Test: Using a beryllium sensitive  and a resistant cell line as representatives of 
the respective groups investigate the changes in expression of p21 mRNA and protein 
levels, measure the amount of beryllium uptake by using ICP-MS, quantify the 
expression of SA β gal. 
3. Research question 3: Is p21 induction and cell cycle arrest induced by beryllium 
a p53 dependent change? 
Test: Knock down p53 expression using siRNA, shRNA and E6 protein 
expression. Use the resulting cell types to study the short term and long term changes in 
molecular events like p21 upregulation and other cell cycle regulator proteins and gene 
expression. 
4. Research question 4: Does beryllium induce apoptosis? 
Test: Measure the activation of caspase 3/7 in cells exposed to beryllium and 
evaluate the extent of apoptosis using TUNEL assay. 
  
3 
CHAPTER 2  REVIEW OF LITERATURE 
BERYLLIUM 
Beryllium  was discovered by Nicholas-Louis Vauquelin in the year 1797. It was 
first separated in 1828 independently by a French chemist AntoineAlexandre-Brutus 
Bussy and German chemist Friedrich Wöhler (De Laeter et al., 2003). 
Beryllium (Be) is an alkaline earth metal with atomic number 4. It belongs to 
Group IIA of the periodic table and has two oxidation states, Be(0) and Be(+2). Due to 
high reactivity of beryllium it is available in approximately 45 mineral forms of which 
Beryllium aluminium silicate (beryl), 3BeO.Al2O3.6SiO2 and Bertrandite (4BeO. 
2SiO2.H2O) are the two commercially important ones. 
Name Chemical Formula 
Molecular 
Weight Physical State 
Solubility 
in Water 
Beryllium Be 9.012 Solid, hexagonal 
structure Insoluble 
Beryllium fluoride BeF2 47.01 
Glassy, 
hygroscopic 
mass 
Very 
soluble 
Beryllium 
chloride BeCl2 79.92 Needles 
Very 
soluble 
Beryllium 
hydroxide Be(OH)2 43.03 
Amorphous 
powder or 
crystalline solid 
Sparingly 
soluble 
Beryllium oxide BeO 25.01 Amorphous powder 
Very 
sparingly 
soluble 
Beryllium 
phosphate Be3(PO4)2 271.03 Crystals Soluble 
Beryllium 
sulfate ** BeSO4.4H2O 177.13 
Tetragonal 
crystals Soluble 
 
  
Table 2-1 Properties of beryllium compounds 
4 
Beryllium is one of the lightest metals. It has a high charge-to-radius ratio and 
forms covalent bonds. Physical properties and solubility of beryllium compounds are 
summarized in Table 2.1.There are nine known radioisotopes of beryllium of which 
beryllium-7 (Be-7) and beryllium-10 (Be-10) are stable with half lives of 53.29 days and 
1.51x106 years (C. R. Hammond, 2011-2012). 
The very first observation of the ability of beryllium to stop cellular growth was 
documented in 1949, using an animal limb regeneration model (Chèvremont and Firket, 
1951; Thornton, 1949). Two years later, the first anti-mitotic effects in a cultured cell 
system were reported in Nature (Chèvremont and Firket, 1951). Historically most of the 
studies on beryllium and its effects on cells have been done with an objective to evaluate 
the toxicity of the molecule and diseases associated with chronic exposure to it (Reeves 
et al., 1967; Schepers, 1961). Typically, such toxicity studies employ metallic beryllium, 
or beryllium salts at very high concentrations. In contrast, only a few studies have been 
done to understand the mechanism of action of low dose beryllium salt as a cell 
proliferation inhibitor (Skilleter et al., 1983; Skilleter and Paine, 1979; Williams and 
Skilleter, 1983). In our research we have attempted to study the effect of beryllium on 
cancer cells. For experiments we have used beryllium sulphate tetrahydrate, a soluble 
form of beryllium. We have used beryllium at very low concentration (approximately 10 
µM) in short time points between 2-7days. Our research focus was on the effect of 
beryllium at low dose, short time point exposures resulting in specific responses in the 
form of gene expression, cell cycle arrest etc. We have discovered that beryllium, just 
like traditional chemotherapy drugs or radiation, can bring about cell proliferation arrest 
or increase in p53 and p21 proteins. However, unlike the actions of chemotherapeutics 
and radiation, these responses due to beryllium are stronger and without DNA damage 
(Gorjala and Gary, 2010).  
5 
p53 
Two different types of studies, one using virologic approach and  the other with a 
serologic approach led to the discovery of p53 in the year 1979 (DeLeo et al., 1979; 
Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979; Rotter et al., 
1980). Observations made immediately after discovery of p53 suggested that it may be 
anti-oncogenic. Data from research in the subsequent years showed that wild type p53 
genes were growth suppressive and several cancer cell lines had mutations in p53 gene. 
For example HeLa cells expressed normal levels of p53 mRNA but undetectable levels 
of protein (Crawford et al., 1981). Human promyelocytic leukemia cells, HL-60, has p53 
gene with large deletions that results in no p53 protein expression (Wolf and Rotter, 
1985). These discoveries led to identification of anti-oncogenic and normal function of 
p53. 
The p53 gene (called TP53) is located on the short arm of chromosome 17 
(17p13) (Isobe et al., 1986). The gene is 22,000 bp long with 11 exons while its mRNA is 
2.2 kb (Lamb and Crawford, 1986). p53 is a 393 aminoacid protein with three 
distinguishable domains. The transactivation domain is located at the amino terminus 
and is targeted by proteins to regulate p53’s function as transcription factor. The DNA 
binding region of p53 is located in the central part of the protein. DNA binding region is 
followed by an oligomerization domain at carboxy terminal region that mediates 
tetramerization of p53. The C-terminal region of the protein contains a negative 
regulatory domain as well as lysine residues that are involved in targeting the protein to 
ubiquitin based degradation by proteosome. 
 In recognition of the significant role of p53 protein in monitoring the integrity of 
genome it has been called the “Guardian of the Genome” (Lane, 1992). Under normal 
conditions the half life of p53 is between 5-30 min. When the cells are exposed to 
genotoxic stress stimuli, cellular levels of p53 protein are found to increase by rapid 
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stabilization. Many post translational modifications stabilize the protein and prevent it 
from degradation. p53 protein activates DNA repair mechanisms, induces or inhibits 
expression of many target genes (El-Deiry, 1998). p21 mRNA, expressed in a p53 
dependent as well as independent manner, transcribes a cyclin dependent kinase (CDK) 
inhibitor which blocks cell cycle progression.  
Depending on the kind and extent of damage induced by the stress, p53 protein 
can induce cell cycle arrest or trigger apoptosis. The decision between cell cycle arrest 
or apoptosis depends on total amount of p53 in cells, extent of DNA damage, sub 
cellular localization and other factors like post translational modifications of the protein 
(Chen et al., 1996; Lassus et al., 1996; Moll et al., 1996; Ostermeyer et al., 1996). While 
cell cycle arrest gives cells an opportunity to overcome damage and survive, apoptosis 
kills the cells thus preventing abnormal cells from surviving. Because p53 causes two 
extreme outcomes for cells it is placed under tight regulation with a very short half-life. 
CELL CYCLE ARREST, SENESCENCE AND APOPTOSIS 
Cell cycle arrest 
A series of phases that an eukaryotic cell crosses before it divides into two 
daughter cells, are together termed as cell cycle. Cell cycle is composed of Gap before 
DNA synthesis(G1), DNA synthesis (S), Gap after DNA synthesis (G2) and mitosis (M). 
Cells have check points during cell cycle to maintain the genomic stability. These 
checkpoints ensure that all the events specific to each phase materialize before the cell 
moves into the next phase of cell cycle (Hartwell and Weinert, 1989). Cell cycle may be 
arrested at these checkpoints if cell does not have enough supply of growth factors or 
has not repaired any cellular damage that might have occurred. Cell cycle check points 
can also activate apoptosis pathway that results in removal of cells that may become 
potentially tumorigenic due to failed genetic repair. 
7 
The first cell cycle check point is at the G1-S transition. This check point is also 
the most extensively studied. The cell cycle arrest at G1-S check point is initiated in 
response to DNA damage. This check point provides enough time to the cell to repair 
the damage and allows it to make a decision about dividing or delaying the division or 
entering a G0 resting phase. During DNA damage the stabilized p53 protein introduces 
G1-S arrest (Baker et al., 1990; Diller et al., 1990). p53 causes this arrest by 
transcriptionally increasing the Cdk inhibitor p21 (El-Deiry et al., 1993). 
Beryllium was shown to induce G1 cell cycle arrest in rat liver cells (Skilleter et 
al., 1983). p53 and p21 were found to be increased by beryllium in human skin and lung 
fibroblast cells (Lehnert et al., 2001; Coates et al., 2007). There were no studies so far 
on the effect of beryllium on the cell cycle of cancer cell lines, until our work described in 
Chapter 4 and published in 2010 (Gorjala and Gary, 2010). 
 
Figure 2-1 Overview of effects of p53 
Senescence 
Cultured primary cells cease to proliferate after a specific number of divisions. 
This property called as replicative senescence is natural to primary cells in culture and 
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was observed in human fibroblast cells by Hayflick and Moorhead (Hayflick and 
Moorhead, 1961). Senescence is different from cell growth arrest both physiologically 
and morphologically. Senescence is triggered by telomere shortening that accrues with 
successive rounds of cell division. Activation of p53 and pRB/p16INK4a pathways is 
required for induction of senescence in human cell lines (Ben-Porath and Weinberg, 
2005; Shay, 1991). Senescence-associated β-Galactosidase activity (SA- β-gal) is an 
important enzymological biomarker for senescence (Dimri et al., 1995). 
A study from our lab group showed that beryllium, at very low doses, can cause 
dose dependent induction of premature senescence in human fibroblasts (Coates et al., 
2007). The study has shown that beryllium causes sustained increase of p53 protein and 
p21 mRNA and protein on short term exposure. Increase of p16Ink4a and Senescence-
associated β-Galactosidase activity were seen during long term exposures. Recent 
studies suggest that activation of p53 in tumor cells leads to tumor regression by 
induction of senescence (Ventura et al., 2007; Xue et al., 2007). 
In present study (Chapter 4) we have data that shows that beryllium causes cell 
cycle arrest and brings about senescence-like state in A172 glioblastoma cancer cell line 
at a low dose of 10 µM. In subsequent work, we found that these cell cycle effects of 
Be2+ are p53-dependent (Chapter 5). 
Apoptosis 
The term apoptosis first proposed by Kerr et al., to describe a form of controlled 
“cell deletion” (Kerr et al., 1972). Since its discovery apoptosis or programmed cell death 
has been recognized as a central process required for normal development of an 
organism and also to maintain homeostasis (Lockshin and Williams, 1965; Jacobson et 
al., 1997; Danial and Korsmeyer, 2004). Apoptosis involves a series of energy 
dependent molecular events that result in various morphological changes that are 
observed and documented using light and electron microscopy (Hacker, 2000). Two 
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major pathways induce and execute apoptosis: (1) extrinsic or death receptor pathway 
and (2) intrinsic or mitochondrial pathway. In addition, there is also a recently discovered 
T-cell mediated cytotoxicity and perforin-granzyme-dependent pathway. Caspases also 
called as executioners of apoptosis are cysteine proteolytic enzymes with specificity to 
aspartic acid residues. Activated caspases cut their targets next to aspartic acid residues 
and can in turn activate other caspases through a cascade pathway. They disrupt 
important pathways by targeting protein kinases, DNA repair and structural proteins of 
the cells ultimately leading to controlled cell death (Cohen, 1997; Nicholson, 1999). 
Caspase activity in the cell is tightly regulated. They are synthesized as inactive 
zymogens and require to be activated to become functional. Inhibitors of apoptosis 
(IAP’s) are a family of proteins that can inhibit activity of caspases to rescue the cell from 
apoptosis (Fuentes-Prior and Salvesen, 2004). 
Evidence from many studies during early 1990’s showed that p53 could control 
apoptosis (Yonish-Rouach et al., 1991; Clarke et al., 1993; Lowe et al., 1993; Symonds 
et al., 1994). However, the exact mechanism as to how p53 chooses between cell cycle 
arrest, senescence and apoptosis is not yet clear. p53 is known to transcriptionally 
activate the proapoptotic genes Bax, Puma, Noxa and Bid (Miyashita et al.; Oda et al., 
2000; 1994; Nakano and Vousden, 2001; Sax et al., 2002). Apart from controlling 
expression of these genes, p53 is also known to regulate components of intrinsic and 
extrinsic pathways of apoptosis (Owen-Schaub et al., 1995; Muller et al., 1998; Kannan 
et al., 2001; MacLachlan and El-Deiry, 2002). 
Our published experimental data showed increase of p53 in beryllium treatment, 
so we have used caspase and TUNEL assays to evaluate whether apoptosis is induced 
by beryllium treatment (Chapter 6). 
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CHAPTER 3  BERYLLIUM SENSITIVITY OF CANCER CELL LINES - CELL 
LINE SURVEY 
INTRODUCTION 
Earlier studies have documented the effects of beryllium on normal cells. One of 
the very early studies of effects of beryllium used time-lapse cinematographic analysis 
and found that beryllium increased the division time of human lung fibroblasts (HFL-1) 
(Absher et al., 1983). Many studies around this period and earlier have linked beryllium 
to two diametrically opposed effects: carcinogenesis and growth inhibition. These 
studies have used various cell types including HFL-1, rat liver cells, skeletal muscle 
cells, macrophages etc, and various salts of beryllium and concentration ranges. A list of 
these studies can be found in paper by Wagoner et al (Wagoner et al., 1980). A study by 
Hart et al (Hart et al., 1982) has documented the effect of beryllium in various forms on 
growth of human lung fibroblasts. A recent study by Coates,S.S et.al has attempted to 
systematically investigate the mechanism of action of beryllium. The study demonstrates 
that beryllium has anti-proliferative effect on normal human lung fibroblasts (Coates et 
al., 2007). The study also shows that there is an interaction between promoter of p21 
gene and p53 protein that results in an increase of p21 gene. In response to beryllium 
treatment the cells exhibit G1 to S phase block leading to G1 arrest. 
The evidence that beryllium causes increase of p53 and p21 proteins and also 
growth arrest at a very low concentration of 10 µM gave us the motivation to study the 
effect of beryllium on cancer cell lines. Our expectation is that beryllium may be able to 
cause a similar increase of p53 and p21 leading to growth arrest in cancer cell lines that 
have functional p53 and p21 genes. The response of cancer cell lines to a drug will be 
different due to the variation in genetic and phenotypic makeup of the cells. With this 
idea we have conducted a survey of responses of 12 cell lines to a range of 
concentrations of beryllium. The objective of this survey study is to verify if different cell 
11 
lines respond differently to beryllium dose and to select a representative cell line for 
sensitive and resistant varieties. 
MATERIALS AND METHODS 
Cell culture media 
RPMI glutamax-1 + 25mM HEPES Cat# 72400, PSF – Gibco antibiotic and 
antimycotic Cat# 15240-062, 0.05% Trypsin-EDTA - Cat# 25300 are purchased from 
Invitrogen - Gibco (Carlsbad, CA). Fetal Bovine serum - Cat# SH30071 and phosphate 
buffered saline – Cat# ARC25970 are from Hyclone Laboratories (Logan, UT). Cyquant 
cell proliferation kit was obtained from Molecular probes. 
S91 cell line requires F-12K Medium (Kaighn's Modification of Ham's F-12 
Medium). S91 cells from stock were thawed into F12K medium supplemented with 15% 
calf serum, 2.5% fetal bovine serum and 1x antibiotic and antimycotic. The cells were 
slowly adapted to regular RPMI medium mentioned above.  
Cell lines  
A172,BT4C, C6, U87MG, PC12, U251, HeLa, PC3, S91 and RKO were 
purchased from ATCC (Manassas, VA). Cell lines SF539, SNB75 were purchased from 
National Cancer Institute. Cells were cultured in RPMI 1640 with Glutamax and 25mM 
HEPES supplemented in 10% FBS and 1%PSF. 
Cell culture and CyQuant assay 
Cells from 100mm plates were trypsinized using 1mL of 0.05% Trypsin-EDTA 
followed by incubation for 3 minutes at 37ºC and 5%CO2. The cells were then 
resuspended in 7 mL of fresh cell culture media. The number of cells was calculated 
using coulter counter and reseeded as required. 
Each cell line used in the experiment was seeded to 60 mm plates and allowed 
to reach 100% confluency. The cells in 60 mm plates were trypsinized by adding 500 µL 
of 0.05% Trypsin-EDTA and incubated at 37ºC and 5% CO2 for 3 minutes. The cells 
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were resuspended in 2.5 mL RPMI. 100 µL of cell suspension was mixed with 9.9 mL of 
Isoton solution and used for taking cell counts in coulter counter. This number is used to 
determine the number of cells required for each cell line to reach 100% confluency. 
Day -1, Seeding to 60 mm plates: The cells from 100 mm plates were trypsinized 
as described before and available number of cells were determined by using coulter 
counter. For each cell type the required number of cells was calculated and twenty four 
60 mm plates were seeded (8 doses x 3 replicates = 24). 
Day 0, Beryllium dosing: RPMI is prepared with 0, 1, 3, 10, 30, 100, 300 and 
1000 µM BeSO4. 10 mL of RPMI at each concentration of BeSO4 is prepared for each 
cell line. The plates seeded on day -1 are screened for uniform distribution and 
confluency. Plates are shuffled, labeled and media is replaced with freshly prepared 
beryllium RPMI corresponding to the labels. Adding beryllium RPMI marks the beginning 
of time point and the day is counted as Day 0. 
Day 3, Transfer to 96 well plate: 60 mm plates were screened to check for 
confluency. The control (0µM beryllium RPMI) plates were trypsinized as described 
before and cell counts determined using coulter counter. Volume of cell suspension 
required to seed 16000 cells per well is calculated and mixed with RPMI to get final 
volume to 200µL. The volume calculated for control plates is used for all concentrations 
of BeSO4. Using the volume calculated for control cells enabled us to transfer the 
number of cells proportional to the ones remaining in the plates after experiencing the 
effect of beryllium. Cells from each 60 mm plate were seeded into 3 replicate wells on 
the 96 well plate. The concentration of BeSO4 was maintained during the transfer of cells 
from 60 mm to 96 well plate.  
Day 5, Standard curve seeding and termination: Approximately 8 hours before 
terminating the experiment, standard curve seeding is done. Untreated cells for each cell 
line are trypsinized from a 100 mm plate and resuspended in RPMI. Cell counts are 
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taken and dilutions are prepared to give 62500, 31250, 15625, 7813, 3906, 1953, 976 
and 0 cells per well. The diluted cells are seeded to three replicate wells. 
Experiment was terminated 8 hours after the standard curve cells were seeded. 
To terminate the experiment the plates were removed from incubator and inverted in 
sink to remove RPMI. 200 µL of PBS is added to wash the cells in all wells. This step is 
done carefully taking precaution not to dislodge any cells. PBS is removed by inverting 
the plate in sink and blotting over stack of paper towels. The 96 well plate is wrapped in 
aluminum foil and saved at -80ºC till further processing. 
CyQuant assay: On the day of assay the plates are removed from -80ºC and 
placed on dry ice for 3 hours, contributing to a freeze-thaw cell lysis step. The plate is 
allowed to thaw to room temperature and 200 µL of CyQuant solution, prepared by 
mixing 19 mL Millipore water, 1 mL CyQuant cell lysis solution and 50 µL CyQuant GR 
dye, is added. The plate is wrapped in aluminum foil and incubated at room temperature 
for 5 minutes and readings are taken on Genios plate reader set to 486 nm and 535 nm 
of excitation and emission wavelengths respectively. 
Data analysis 
The fluorescence reads from wells with standard curve were plotted on y-axis 
with corresponding cell number on x-axis. A linear regression trend line was added and 
the slope in resulting equation was used to calculate the cell number in each well. 
Average of replicates is plotted for all cell lines. 
RESULTS 
Beryllium in the form of BeSO4.4H2O was diluted from primary stock to give final 
working concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000µM. The cells were cultured 
in the presence of beryllium in 60 mm plates for 3 days and then reseeded to 96 well 
plate as described earlier. At the end of 5 days under beryllium influence, the total DNA 
content of cells in each of the wells of the 96 well plate was calculated using Cy-Quant 
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assay, which employs the dsDNA dye CyQuant. The volume of cell suspension 
transferred from 60 mm plates to the wells of 96 well plate is same for cells at all 
concentrations of BeSO4. This ensured that the number of cells transferred to  96-well  
plate are proportional to the number of cells remaining attached to the 60 mm plate at 
the end of day 3. The total period of exposure to the drug was for 5 days. The 
concentration of BeSO4 and the proportion of number of cells attached to 60mm plates 
are maintained during the transfer of cells from 60 mm plates to the wells of 96 well 
plate. This assay measures the differential growth of treated cells during the 5 day 
treatment period. 
The results shown in Fig 3.1 and 3.2 demonstrate that all cancer cells are not 
sensitive to beryllium. Out of 12 cell lines used for this survey 6 cell lines were 
considered sensitive and 6 cell lines were resistant. The classification was done based 
on IC50 values of beryllium for each cell line. The IC50 value represents the 
concentration of drug required to produce 50% inhibition of cell number (as judged by 
total DNA content) during the growth period in the 96-well plates. A172, a human 
glioblastoma cell line and SF539, a glioma cell line from human, were the most sensitive 
of all the cell lines. RKO,a human colon carcinoma and PC-12, a pheochromocytoma 
from rat were the most resistant.  
DISCUSSION 
The green fluorescent dye in the Cy-Quant reagent binds to the DNA in cells. 
The amount of fluorescence is directly proportional to the number of cells in the wells. 
Cells were serially diluted and seeded to generate values for standard curve. The 
equation from standard curve is used to calculate the number of cells in control and 
beryllium dosed wells. 
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Figure 3-1 Beryllium sensitive cell lines 
 A172 (human, glioblastoma) and SF539 (human, glioma) were the most sensitive cell lines. Both 
of these cell lines showed highest sensitivity to beryllium by showing decrease in cell number 
even with IC50 values of 3.4 and 5.1 µM respectively for beryllium. The data are presented as 
mean +/- Standard Deviation. 
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Figure 3-2 Beryllium resistant cell lines 
RKO (human, colon carcinoma) and S91 (pheochromocytoma, rat) were the most resistant cell 
lines. Both of these cell lines showed resistance and ability to survive presence of beryllium with 
IC50 values of 440 and 290 µM of BeSO4. The data are presented as mean +/- Standard 
Deviation. 
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Role of p53 in the cellular response to the treatment of cells with beryllium has 
been documented in earlier studies (Gary and Kindell, 2005; Lehnert et al., 2001). Table 
3.2 documents the p53 status of the different cell lines used in this survey. It is possible 
that the difference in the status of p53 might have contributed to the variation in 
response of cell lines to beryllium treatment. However, with the data presented here, 
there is no correlation between the p53 status and beryllium resistance. A detailed study 
is required to thoroughly understand the mechanism of action and also to explain the 
differences in response to beryllium. 
For further study about the mechanism of action of beryllium, we chose to use 
human cell lines A172 and RKO as representatives of sensitive and resistant cell lines, 
respectively. The choice was based on the IC50 values listed in Table 3.1. Both these 
cell lines express functional p53 protein (Mirzayans et al., 2005; Ishii et al., 2006; Liu and 
Bodmer, 2006).  
The data presented in later chapters show that some of the effects of beryllium 
include cell cycle arrest and p53 dependent induction of p21. It has been established in 
earlier studies that p53 protein plays an important role in cell cycle arrest and cell lines 
having mutated p53 or lacking p53 may show some resistance to action of cytotoxic 
drugs (Amundson et al., 1998; Shaw, 1996; Brosh and Rotter, 2009). 
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S.No Cell Line 
IC 50 Value 
(µM of beryllium) 
1 A172 3.4 
2 SF539 5.1 
3 BT4C 8.5 
4 C6 8.9 
5 U87MG 12 
6 SNB75 22 
7 PC12 56 
8 U251 59 
9 HeLa 72 
10 PC3 180 
11 S91 290 
12 RKO 440 
Table 3-1 IC50 values of BeSO4 for different cell lines 
Different cell lines have different levels of sensitivity to beryllium treatment. Some cell lines can 
tolerate very high concentration of beryllium while some are sensitive to its presence even in very 
small concentrations. The IC50 values are calculated from the data used to plot Fig 3.1 and 3.2 
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S.No 
Cell 
Line Type, Origin Species 
ATCC Cat 
# TP53 status References 
1 A172 Glioma, Brain 
Homo 
sapiens CRL- 1620 Wild Type  
(Mirzayans et 
al., 2005; 
Ishii et al., 
2006) 
2 SF539 Glioma, Brain 
Homo 
sapiens 
NCI-60 cell 
line * 
Single mutation, 
Frame shift 
mutation at 
position 342 
deletion of 1 A 
(Forbes et 
al., 2010) 
3 BT4C Glioma, Brain 
Rattus 
norvegicus 
   
4 C6 Glioma, Brain 
Rattus 
norvegicus  CCL-107 Wild Type 
(Asai et al., 
1994) 
5 U87MG Glioma, Brain 
Homo 
sapiens HTB-14 
Wild Type, 
Homozygous 
(Ishii et al., 
2006; Van 
Meir et al., 
1994) 
6 SNB75     
NCI-60 cell 
line * 
Mutant p53, 
position 258 G 
to A 
(O'Connor et 
al., 1997) 
7 PC12 
Pheochromocyt
oma 
Rattus 
norvegicus  CRL-1721 
Functional p53 
protein 
expressed 
(Eizenberg et 
al., 1996) 
8 U251 Glioma, Brain 
 Homo 
sapiens 
 
Mutant p53, 
position 273 R 
to H 
(Brazdova et 
al., 2009) 
9 HeLa 
Adenocarcinom
a, Cervix 
Homo 
sapiens CCL-2 
p53 mRNA 
expressed but 
protein is 
degraded due to 
complexing with 
HPV proteins 
(Scheffner et 
al., 1991) 
10 PC3 
Adenocarcinom
a; Metastasis to 
bone, Prostate 
Homo 
sapiens  CRL-1435 
No p53 mRNA. 
Single copy of 
p53 gene has 
deletion at 
codon 138 
resulting frame 
shift placed a 
stop codon at 
169. 
(Carroll et al., 
1993; Isaacs 
et al., 1991) 
11 S91 
Melanoma , 
Skin 
Mus 
musculus CCL-53.1  
No ref 
available 
12 RKO 
Carcinoma, 
Colon 
Homo 
sapiens CRL-2577 Wild type p53 
(Liu and 
Bodmer, 
2006) 
Table 3-2 p53 status of different cell lines used in the survey 
p53 plays a significant role in the effectiveness of drugs that interfere with cell cycle controlling 
pathways. 
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CHAPTER 4  BERYLLIUM INDUCES SENESCENCE LIKE STATE IN 
GENETICALLY SENSITIVE TUMOR CELL LINES – COMPARATIVE STUDY 
BETWEEN A172 AND RKO * 
INTRODUCTION 
Normal somatic cells undergo cell division, after a specific number of divisions 
they enter a phase called cellular senescence. Senescence is characterized by very long 
population doubling times and changes in morphology of cells however, the cells are 
metabolically active (Campisi, J.,2001). Replicative senescence is the name given to the 
process that is a result of decreased ability of normal cells to divide due to shortening of 
telomeres after multiple cell divisions (von Zglinicki, 2001). Senescence induced by 
factors other than telomere shortening is known as premature senescence or 
accelerated senescence. Senescence in general is believed to be a tumor suppressor 
mechanism developed by cells. When normal cells undergo mutations that give them 
ability to override the senescence mechanism they turn into cancer causing cells. 
It is now established that some types of tumor cells can be made to become 
senescent by exposing them to drugs, radiation or genetic manipulation. Some of the 
therapeutic agents that are used in treatment of cancer function like senescence 
inducing agents. These drugs inflict DNA damage which in turn activates the p53 
dependent senescence pathways in vitro (Chang, B. D., 1999). p53 is at a pivotal point 
______________________________________________________________________ 
* NOTE: This chapter corresponds to the content of the published paper: 
Gorjala and Gary (2010). Beryllium sulfate induces p21CDKN1A expression and a 
senescence-like cell cycle arrest in susceptible cancer cell types. Biometals 23: 1061-
1073. 
Two versions of this manuscript were written independently. The version of the 
manuscript as it appears in Biometals was written by Dr. Ronald K. Gary. The alternate 
version of the manuscript, which appears here as Chapter 4, was written by Priyatham 
Gorjala. 
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in intracellular signaling network that detects DNA damage and controls the progression 
of cell cycle (Di Leonardo, A. et al, 1994). The p53 regulated cell cycle arrest can be 
initiated by various means that include DNA damage, oxidative stress, HDAC inhibitors 
etc (Drayton S et al 2002). p53 and p21 play a key role in induction of senescence in 
normal cells and are also responsible for senescence in human tumor cells treated with 
therapeutic drugs (Chang, B. D., 1999). p53 senses DNA damage due various stress 
stimuli, short telomeres or activated oncogenes. The activated p53 mediates its cell 
cycle arresting actions through p21. p21, a cyclin dependent kinase inhibitor, is famous 
for its role in cell cycle arresting abilities. Many studies have proved that p21 causes G1 
phase arrest in cell cycle. G1 phase arrest occurs as a result of cyclin dependent kinase 
inhibition in the initial phases of senescence and the changes are coordinated by action 
of p21 during the early phases of senescence (Dulić V et al., 2000).  
Induction of cellular senescence pushes cells from actively proliferating state to a 
non-proliferating senescent state. Induction of cellular senescence in tumor cells is being 
considered as well as researched aggressively as a treatment option. Apoptosis is 
another process that can be used to remove actively dividing cells from system but, 
senescence is unique in that the process helps in retaining the functional cells in the 
system. 5-fluorouracil, doxorubicin, aphidicolin and cisplatin are examples of many drugs 
found to induce cellular senescence in tumor cells. These drugs show their effect due to 
the interactions with DNA (Roninson IB et al., 2001). A simple element beryllium was 
found to increase the levels of p53 and p21 (Lehnert et al., 2001). Cell cycle arresting 
properties of beryllium were first reported by Hart and Skilleter et al (Hart et al., 1982; 
Skilleter et al., 1983). Coates SSA et al., reported beryllium as a new premature 
senescence inducing drug in normal young Human Fibroblast (HFL-1) cells for the first 
time (Coates SSA et al., 2007). 
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In this study we have investigated the efficiency of beryllium as senescence 
inducing agent in tumor cells. Our study also shows that effects of beryllium, though very 
strong even at significantly lower doses, are not due DNA damage. We also found that 
effect of beryllium is not same on all cell lines but, depends on the sensitivity of cell line. 
For our investigation, we have used A172 and RKO cell lines as representatives of 
beryllium sensitive and resistant cell lines respectively. Beryllium is used in form of 
BeSO4, which is a highly soluble form. 
MATERIALS AND METHODS  
Cell Culture 
Wild type A172 and RKO cells were used for experiments. The cell lines were 
propagated RPMI1640 with GlutaMAX supplemented with 10% fetal bovine serum and 
1% PSF. The cells were cultured in 100 mm dishes at 37ºC with 5% CO2. 0.05% trypsin 
EDTA was used for trypsinizing the cells when splitting. 
Beryllium treatment 
BeSO4.4H2O from Fluka was used to prepare a stock solution. Beryllium stock 
solution was diluted to required concentration in RPMI just before dosing. 
The cells for control plates and beryllium dosed plates were taken from same cell 
stock and seeded to plates. After allowing the cells to attach the plates were shuffled, 
labeled and media changed. The control plates receive normal RPMI with no beryllium 
and the beryllium dosed plated receive respective concentration of beryllium RPMI. 
UV and IR treatment 
For ionizing radiation dosing, the Cabinet X-Ray system, model Rx-650, by 
Faxitron X-ray corp was used. For UV dosing a 15 W UV light source (Sankyo Denki 
G15T8) was used and dosage was monitored using UVX radiometer, model UVX-25. 
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Cell count experiment 
The cells were cultured in 60 mm plates. The dishes were seeded from single 
cell stock and left for approximately 24 hours allowing the cells to attach. The plates are 
then shuffled, labeled and dosed with beryllium. 72 hours after dosing the cells were 
trypsinized and resuspeneded in RPMI with or without beryllium. Exactly same volume of 
cell suspension from all plates was seeded to 96-well plate. Each plate was seeded in 
triplicate on the 96well plate and allowed to grow for another 48 hours. 
The experiment was terminated at the end of 5th day. Cell counts were obtained 
by measuring fluorescence using CyQUANT Cell proliferation assay kit (Invitrogen 
cat#C7026). Number of cells attached to plate was estimated using a standard curve 
generated from serial diluted cells seeded into the same plate 12hrs before termination 
of experiment.  
Western Blot analysis 
Protein extracts of cells treated with beryllium were made by in M-PER (Pierce 
cat#78501) with protease (Halt protease inhibitor cocktail kit, Pierce cat#78410) and 
phosphatase inhibitors (Sodium Fluoride 20 mM, Beta Glycerol phospate 10 mM, 
Sodium ortho vanadate 0.1 mM, Paranitro phenyl phospate 20 mM). The cell suspension 
was lysed by pippetting vigorously. The lysed cell suspension was centrifuged and total 
protein concentration in supernatant was measured by using BCA assay (Thermo 
scientific # 23227). 
Normalized samples were loaded onto 8% gels for probing with Actin, p53 and 
10% gels for probing with p21 protien levels. The gels were electrophoresed and 
transferred to polyvinylidine difluoride membrane (Millipore cat#IPFL20200). The 
following primary and secondary antibodies were used for probing. 
p53: Mouse monoclonal IgG2a (Cat# SC-126 Santa cruz biotechnology, inc) and 
Goat anti-mouse IgG peroxidase (Cat#A9917 Sigma Aldrich) 
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p21: Mouse monoclonal IgG2b (Cat# SC-6246 Santa cruz biotechnology, inc) 
and Goat anti-mouse IgG peroxidase (Cat#A9917 Sigma Aldrich) 
Actin: Goat monoclonal IgG2b (Cat# SC-1615 Santa cruz biotechnology, inc) and 
bovine anti-goat IgG-HRP (Cat# SC-2350 Santa cruz biotechnology, inc) 
P53 ser 15: Rabbit polyclonal (Cat# 9284 Cell signaling technology) and Goat 
anti-rabbit IgG- HRP (Cat# 31460 Thermo Scientific) 
 γH2AX: Rabbit IgG (Cat# DR1017 Calbiocehm) and Goat anti-rabbit IgG- HRP 
(Cat# 31460 Thermo Scientific) 
The blots were developed using ECL plus reagent (GE health care amersham 
cat# RPN 2132). Imaging was done by using Typhoon variable mode imager with 
excitation wavelent of 457nm and emission filter set to 520nm. 
All experiments were setup in duplicates for checking reproducibility of the 
results. 
Real time PCR 
Total mRNA was extracted from control and dosed cells using Rneasy Mini Kit 
and QIA-shredder (Qiagen cat #74104 and 79654). Real time PCR was performed on 
same quantity of cDNA sample reverse transcribed from total mRNA using QuantiTect 
Reverse Transcription Kit (Qiagen cat# 205311) and QuantiTect SYBR green PCR kit 
(Qiagen cat# 204143). The primers used were Actin, GAPDH, p21 (QuantiTect Primer 
assays – QT00095431, QT00079247, QT00062090). 
The following thermal cycling profile was used for amplification and detection - 
Initial Denaturation at 95ºC for 15 minutes. 40 repetitions of denaturing at 94ºC for 15 
seconds, Annealing at 55ºC for 30 seconds, extending at 72ºC for 30 seconds. Final 
denaurataion at 95ºC was done for 1 minute and final extention was done at 72ºC 1 
minute. Melt curve analysis was done starting from 55ºC for 10 seconds with increasing 
set point temperature after cycle 2 by 0.5ºC.  
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Flow cytometry 
The control and dosed cells were trypsinized and 5 x105 cells were used for 
staining with propidium iodide. Dosed cells were treated with 10 µM BeSO4 for 3 days. 
The cells were washed in cold phosphate buffered saline twice and fixed using 95% 
ethanol. Before staining the cells were washed in phosphate buffered saline and 
resuspened in 1% Triton X-100 and treated with RNAse. The cells were stained with 100 
µg/mL of propidium iodide. 
Inductively coupled plasma mass spectrometry (ICP-MS) 
A172 and RKO cells were seeded into 100 mm plates. After allowing the cells to 
attach the media was replaced with or without beryllium as required. 0, 10, 30 or 100 µM 
concentrations were used and each concentration in triplicate were setup for this 
experiment. After 24 hour and 48 hour time periods the media was removed and each 
plate washed 3 times with RPMI only (without FBS and PSF) and 3 times with 
phosphate buffered saline. 300 µL of M-PER buffer without protease and phosphatase 
inhibitors was used for each plate and cells were scrapped and transferred into 1.5 mL 
tubes. The samples were vortexed vigorously and centrifuged. 250 µL of supernatant 
was diluted by adding to 19.75 mL of millipore water and 10 µL was used for protein 
content estimation by BCA assay. Sample of 25 mL is filtered through 0.45 micron glass 
filter into a new pre-rinsed tube. A special wash control plates were also run in parallel to 
monitor the washing steps. Wash control plates are treated identical to the 0µM plates in 
setup, media changes and harvest except that, just before harvest the cells received 
beryllium RPMI for exactly 1 minute. Reading from these plates shows the amount of 
beryllium that was trapped between the cells and carried over to lysates. 
Total beryllium uptake is measured by using Inductively Coupled Plasma-Mass 
Spectrometer. Standard curve was setup with 0, 10, 50, 100, 500, 1000 nM of beryllium 
in Millipore water. The readings taken were normalized to total protein content. 
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Senescence Associated β-Galactosidase activity assay 
A172 cells were setup with doses of 0 and10 µM beryllium. RKO cells were 
dosed with 0,10 and 100 µM beryllium. The following HFL-1 cells were used 
comparision. 
HLF-1 cells at passage 16(young) and HFL-1 passage 31(senescent) at harvest 
for 6 day, HFL-1 passage 18 (young) and HFL-1 passage 32 (senescent) at harvest for 
12 day assay. 
Senescence Associated β-Galactosidase activity (SA β-Gal activity) was 
measured in protein normalized samples. The quantitative assay was performed 
according to method previously described (Gary and Kindell, 2005). 
Fluorescent microscopy H2AX ser 139 phosphorylation 
The control and test cells seeded and dosed in lab-tek chamber slides were 
washed with cold P.B.S, 3 times and fixed with 4% formaldehyde and permeabilized with 
0.5% TritonX. The cells were then incubated in 10% Normal Goat Serum to prevent 
nonspecific binding. Primary anti-body treatment was given for 1 hour followed by 
Secondary anti-body at room temperature for 45 min in dark. ProLong gold antifade was 
used to seal the coverslip to slide and then the slide was taken for imaging. 
Statistical Analysis 
Data sets with two dosage groups at each time point were analyzed by unpaired 
t-test, two tailed. Data sets with more than two groups were analyzed using one-way 
ANOVA with a post-hoc Bonferroni's multiple comparision test (P < 0.05 considered 
significant). 
RESULTS 
Beryllium dosing stops tumor cells from dividing 
Beryllium sulfate causes the human fibroblast cells to enter into a premature 
senescence in a dose dependent manner (Coates SSA et al., 2007). To investigate if 
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BeSO4 has similar effect on tumor cells we have used A172 and RKO cell lines for our 
study. The results (Fig 4.1) show that A172 is sensitive to presence of beryllium even at 
1 µM concentration where as RKO cell line is able to resist the effects even at a high 
concentration of 100 µM. This simple but effective cell count experiment clearly shows 
the difference in the effect of beryllium on the two cell lines. Death of cells in test 
samples is not the only reason for decreased cell counts in test samples compared to 
control samples. The number of cells that do not undergo cell division in test samples 
cumulatively resulted in lower counts at the end of 5 day time point. When observed 
under microscopes there were dead floating cells at higher concentration of beryllium 
but, at lower concentrations the test plates looked almost identical to control plates with 
lower confluency and lower number of mitotic cells. 
Beryllium causes G1 block in tumor cells 
To verify if beryllium actually causes a block in cell division we performed a flow 
cytometry analysis on the sensitive cell line, A172. Total of 40,000 cells from control and 
test samples were analyzed and counted. There is a 19% increase in cells blocked at G1 
phase in 10 µM beryllium treated samples compared to controls (Fig 4.2). These results 
show that there is accumulation of cells in G1 phase of cell cycle when A172 cells were 
treated with beryllium. 
Beryllium causes an increase in p53 and p21 in tumor cell lines 
It is a very well established fact that increased active p53 protein in cells usually 
leads to G1 block of cell cycle through p21. The western blot data (Fig 4.3) shows an 
increase in p53 and also p21 proteins in A172 cell lines treated with 10 µM concentration 
for 24 and 48 hours. The increase is in correlation with the observation of G1 block in 
test sample made using flow cytometry data. The more resistant RKO cells on the other 
hand do not show any significant changes in levels of p53 or p21 proteins. RKO cells  
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After 5 days of treatment with beryllium RPMI, plates with A172 cells have significantly 
lower cells even at a very small dose of 1µM. On the other hand RKO cells seem to 
tolerate a very high dose of 100 µM beryllium. The data are presented as mean +/- 
Standard Deviation.
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Figure 4-1 Cell count after 5 day beryllium treatment 
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Comparison between control (A) and cells treated with 10 µM BeSO4 (B) for 3 days 
shows that there is an accumulation of cells in G1 phase in Beryllium treated cells. 
 
Figure 4-2 Beryllium can induce G1-S accumulation of cells 
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Figure 4-3 Beryllium can induce p53 and p21 in senesitive cell types 
A. RKO cells dosed with beryllium at 0 (control), 10 and 100 µM for 24 (Day 1) and 
48hours (Day 2). The dosed cells show no observable change in levels of both p21 
and p53 protein compared to control cells. The last two lanes show blots of lysate 
extracted from cells dosed with IR (X-ray at 5 gray) and UV (at 10 J/m2) radiation. IR 
and UV lane extract shows increase in p53 and p21 protein proving the presence of 
functional p53 –p21 system in the RKO cells. 
B. A172 cells dosed with beryllium at 0 (control) and 10 µM for 24 (Day 1) and 48hours 
(Day 2). Compared to control samples a very large increase in the amount of p21 
and p53 protein is seen even at a very low dose of 10 µM BeSO4.  
C. In a separate experiment cell lysate of A172 cells treated with 0 and 10 µM of 
beryllium for 24 hours and 48hours was analyzed using western blot for checking the 
levels of phosphorylation of p53 at ser15. The results show a clear increase in 
BeSO4 treated samples 
Actin levels in the samples were used to check for protein normalization accuracy. 
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were treated with ionizing radiation (X-rays – 5 Gy) and UV (10 J/m2). This additional 
dosing shows that RKO cells had functional p53 and p21 proteins. 
To measure the changes in levels of p21 Reverse transcription polymerase chain 
reaction (RT-PCR) is used (Fig 4.4). For the sensitive A172 cells a 135% and 225% 
increase compared to control is seen at 24 hrs and 48hrs respectively. The resistant 
RKO cells do not show increase of p21 compared to respective controls. The RKO cells 
have functional p21 system which is resulting in 480% and 127% increase compared to 
control when dosed with UV and IR respectively. 
Beryllium treatment causes SA β–gal expression in tumor cells 
Experiments by Coats SSA et al have shown that SA β–gal expression is 
increased in human fibroblast cells upon exposure to low concentrations of beryllium 
(Coates SSA et al., 2007). To check if a similar response is elicited in tumor cell lines, 
SA β-gal assay is performed on A172 and RKO cells with HFL-1 young presenescent 
and senescent cells as positive controls. 
The increase in SA β-gal levels in A172 is comparable to response seen in HFL-
1 young cells treated with same concentration of beryllium. RKO cells on the other hand 
have very less quantity of SA β-gal in control cells and show no change in SA β-gal 
levels even at a high dosing concentration of 100 µM (Fig 4.5). 
Beryllium does not cause DNA double strand breaks 
Increase in concentration of p53 and subsequent increase of p21 is a typical 
response seen in case of DNA double strand breaks. To investigate the possibility 
beryllium causing DNA double strand breaks to bring about the pause in cell cycle we 
checked the phosphorylation of ser 139 in H2AX. H2AX is histone protein and its 
phosphorylation at ser 139 is used to identify cells with DNA double strand breaks. DNA 
damaging agents Etoposide, Camptothecin and UV dosing were used to generate  
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A. A172 cells were treated with 0(control) and 10 µM beryllium and GAPDH and p21 
levels of mRNA were measured. From the plot it is obvious that there is significant 
increase in mRNA levels of p21 in beryllium dosed cells. 
Figure 4-4 Beryllium causes changes in p21 gene expression 
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C. RKO cells were treated with 0(control), 10 µM and 100µM. The mRNA levels 
measured using Real time PCR shows that, there is no significant increase in p21 even 
at 100 µM dose of beryllium. 
E. To verify if RKO cells have has functional p21 genes RKO cells were exposed to 
UV, IR and mRNA levels measured. 
B,D,F Actin is a house keeping gene used and GAPDH mRNA levels were used to 
normalize the data. 
The data are presented as mean +/- Standard Deviation. Statistically significant 
differences are indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Fluorescence readings were taken at the end 12 day treatments on cell lysates at 
0,30,60,90,120 minute time points. The data presented here is from reading taken at the 
end of 120 minutes. The signal was strongest at end of 120 minutes and the signal 
strength at other time points was relatively weak but proportional to the data shown here. 
HFL-1 senescent cells were generated by propagating the young cells till they reached 
passage 35 by the time of harvest. HFL-1 used as positive control for the assay. A172 
Young cells were at passage 18 by the time of harvest. The young HFL cells were 
treated with 10 µM and cells were treated with 10 µM beryllium and RKO cells were 
given a low dose of 10 µM and high dose of 100 µM beryllium. 
 
The levels of SA β-gal levels were measured by using 4-methylumbelliferyl-β-d-
galactopyranoside (MUG). The final values of fluorescence are normalized to the total 
protein content of the respective samples. The data are presented as mean +/- Standard 
Deviation. Statistically significant differences between control and treatment groups are 
indicated as * P < 0.05, ** P < 0.01, *** P < 0.0001. 
 
  
Figure 4-5 SA β-gal is induced in sensitive cancer cell types by beryllium 
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positive control samples for western blot and etoposide only for immunofluorescence 
experiments. 
Both 24 and 48 hours treatment even at a very high concentration of 300µM 
beryllium failed to show any increase of H2AX ser 139 phosphorylation. The positive 
controls, Etoposide, camptotehcin at 10 µM each for 24 hours and UV dosed samples, 
on the other hand have shown significant increase of H2AX ser 139 phosphorylation (Fig 
4.6). 
Immunofluorescence microscopy is usually used to check for Ser 139 
phosphorylation in H2AX. Our experiments with 10 µM and 300µM beryllium for 24 
hours have resulted in images looking similar to control samples while bright foci can be 
seen in positive control i.e., 10 µM Etoposide samples. 
Both Western blotting and Immunofluorescence microscopy results show that 
BeSO4 even a very high concentration of 300µM may not be inducing any double strand 
breaks.  
All the observations made in the above experiments show that A172 is affected 
by beryllium more than RKO. ICP-MS was used to measure the intracellular 
concentration of beryllium in each cell line (Fig 4.7). This was done to find out if there is 
any difference in uptake of beryllium by the cell lines that is resulting in the difference in 
sensitivities. The final values of beryllium concentration inside the cells were normalized 
to the total protein content of the cells used for experiment. At a lower concentration of 
10 µM A172 cells appear to be taking up more beryllium compared to RKO cells but, at 
higher concentration of 100 µM both cell lines are taking up approximately equal amount 
of the drug (Fig 4.7). The various effects of beryllium observed at 100 µM in RKO cells 
are insignificant compared to the response shown by A172 at 10 µM concentration (Fig 
4.1, 4.3, 4.4, 4.5). These two observations, almost same amount of beryllium uptake but 
difference in response of the two cell lines suggest that beryllium may be influencing a 
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pathway that is present is A172 but not in RKO. This suggests that the difference in 
uptake of beryllium is not a cause for the observed difference in the effects between the 
two cell lines  
DISCUSSION 
Constant long term exposure to beryllium will show its effects as chronic 
beryllium disease which in some cases may be lethal. Beryllium is carcinogenic at high 
concentrations but has the ability to induce premature senescence at lower doses 
(Coates SSA et al., 2007). 
Our initial experiments with tumor cells and beryllium show that it is able to stop 
tumor cells from proliferating (Figure 4.1). Beryllium shows difference in its effects 
depending on the type of cell line. The decrease in cell proliferation is more in sensitive 
cell line A172 than the resistant line RKO. Only the cells that are attached to the dish are 
used to generate the cell count of viable cells. The decrease in cell count at lower doses 
is not due the cell death as it appears from the graph (additional data not shown). The 
lower cell counts in beryllium treated samples can be explained by arrest of cell division 
at G1 phase (Figure 4.2). The major contributor for decrease in counts in the cell count 
experiment is the decrease in cells that undergo division. 
One significant event that occurs within 24 hours after treating tumor cells is 
increase in p53 and p21 proteins (Figure 4.3). The change is more pronounced in A172 
cells compared to RKO. p53 protein shows its effect on cell cycle by activating 
transcription of p21, a very important protein downstream of the p53 controlled 
senescent or apoptosis pathways.  
The amount of available active p53 inside the cell is increased by 
phosphorylation of residues at different positions with help of various kinases. These 
changes prevent degradation of p53 resulting in its accumulation. Status of Ser 15 
phosphorylation is verified to estimate stabilization of p53 (Shieh SY et al., 1997). We  
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Figure 4-6 Beryllium does not cuase DNA damage 
A. A172 cells were treated for 24 and 48 hour period with the above shown doses of 
beryllium.  Cells treated  with 10 µM concentration of Etoposide and Camptothecin 
for 24 hours  along with UV dosed cells were used as positive controls. The lanes 
with beryllium treated samples show no increase in H2AX ser 139 phosphorylation 
compared to negative control lanes. The positive control samples treated with 
Etoposide, Camptothecin and UV light show enormous increase in H2AX Ser 139 
phosphorylation. 
B. A172 cells treated with 0µM used as control and 10 µM or 300µM beryllium used as 
test and 10 µM Etoposide as positive control were analyzed using 
immunofluorescence microscopy.  The cells were fixed, permeabilized and treated 
with primary antibody against gamma H2AX and a FITC bound secondary anti body. 
Double strand DNA breaks trigger phosphorylation of H2AX at ser 139 position and 
will be seen as bright foci, as in case of Etoposide 10 µM treated cells. 
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Figure 4-7 Differential uptake of beryllium is not a cause for difference in A172 and RKO 
sensitivities 
At 10 µM beryllium concentration, it appears that A172 cell line is taking up higher beryllium 
compared to RKO cell line. But the 100 µM data shows clearly that difference in uptake of the 
beryllium is not significant between the two cell lines.  
The wash control data demonstrates the efficiency of wash procedure in removing Be2+ from the 
exterior surface of cells. The cells used for 30 wash control are cultured in 0µM but exposed to 
BeSO4 for 1 minute then washed according to protocol and prepared for ICP-MS analysis. 
The data are presented as mean +/- Standard Deviation. 
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found that beryllium treatment causes phosphorylation of p53 at ser15 (Figure 4.3C).p21 
levels are increased by transcribing p21 mRNA which is regulated by stabilized p53. The 
increase in p21 protein levels corresponds to the increase in p21 mRNA levels (Fig 4.4). 
The amount of p21 mRNA is 135% more at 24 hours and 225% more at 48 hours 
compared to control. The RKO cells show no change even a 100µM, 10 times higher 
dose than the concentration required bringing about a response in A172. RKO cells have 
functional p53 - p21 system which is evident from the response to UV and IR dosing 
verified by western blotting and RT-PCR experimental data. These changes are in 
agreement to a well documented observation that initial increase in p21 inhibits 
progression of cell cycle in the cells (Di Leonardo, A. et al, 1994). 
SA-β-gal is used as an important biomarker for senescence. It is found to be 
increased only in senescent cells and not in actively dividing or terminally differentiated 
cells (Dimri GP, 1995). Recent studies show that drug induced increase in levels of SA-
β-gal can be used as marker for estimating the senescent like cell cycle arrest in cancer 
cells. The increased level of senescence-associated beta-galactosidase seen in these 
senescent cells is due to the accumulation lysosomal β-galactosidase (Lee BY et al., 
2006). Increased lysosomal activity is observed in the cells that are senescent stage 
(Gerland et al., 2003). Our hypothesis that beryllium induces senescent-like state in 
cancer cells is corroborated by the recent finding that suggests intracellular 
concentration of beryllium may not be able to induce apoptosis (Ding J et al., 2009). We 
have found that long term treatment of A172 cells with beryllium induces expression of 
SA-β-gal (Fig 4.5). The level of SA-β-gal expressed is comparable to that seen in young 
HFL-1 cells. RKO on the other hand did not show any change in SA-β-gal levels. No 
change of SA-β-gal level in beryllium treated RKO samples is consistent with the actively 
dividing cells seen in that cell line. 
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The drugs that are used in therapy for cancer for their ability to induce 
senescence usually cause DNA damage. The DNA damage subsequently results in 
activation of p53 based pathway to induce senescence. DNA damage can be monitored 
by checking the phosphorylation of ser 139 residue on histone H2AX (Rogakou EP et 
al., 1998). We have used H2AX Ser 139 phosphorylation as marker for DNA strand 
break to verify if beryllium was causing DNA damaging in the sensitive cell line i.e., 
A172. Cell cycle arrest-inducing low dose of BeSO4 at 10 µM and a very high dose of 
100 µM and 300 µM were used. Results from both western blotting as well as 
immunofluorescence suggest that beryllium does not cause any DNA damage. 
The difference in magnitude of the effect of beryllium observed in A172 and RKO 
is not due to difference in uptake of beryllium as evident from ICP-MS study. It is 
possible that the difference is due to the variable genetic sensitivities of the cell lines. In 
the present study we were able to confirm that beryllium is able to induce senescence in 
sensitive cancer cell lines. The mechanism by which Be2+
 
is doing this is not yet clear but 
the results indicate that the mechanism involves no DNA damage that is seen regularly 
with other senescence inducing drugs. The unique ability of beryllium to activate 
senescence signaling pathway through p53 without inflicting DNA damage makes it 
novel tool to investigate the mechanism of senescence induction in greater detail. 
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CHAPTER 5  CELL CYCLE INHIBITING EFFECTS OF BERYLLIUM ON 
CANCER CELLS ARE P53 DEPENDENT 
INTRODUCTION 
Beryllium, when administered to cells in the form of beryllium salts was found to 
inhibit the growth in human fetal lung fibroblast  and rat hepatic cell lines. Cell cycle 
arresting properties of beryllium were first reported by Hart and Skilleter et al (Hart et al., 
1982; Skilleter et al., 1983). Beryllium in the form of BeSO4 was reported as a new 
premature senescence inducing agent in normal young Human Fibroblast (HFL-1) cells. 
Further, it was demonstrated that BeSO4 was influencing the cell cycle progression while 
causing an increase of cell cycle inhibitor protein p21 and a decrease in DNA synthesis, 
resulting in an induced premature senescence. BeSO4 was found to increase the levels 
of p53 and p21 and inhibit growth in normal human lung fibroblast (Lehnert et al., 2001). 
It was also discovered that p53 protein binds to the promoter region of p21 thus 
regulating its transcription in the presence of BeSO4 (Coates et al., 2007). In an earlier 
study we have investigated the ability of BeSO4 to induce senescence like state in 
susceptible cancer cell lines. BeSO4 was found to stabilize p53 and induce expression of 
p21 followed by induction of senescence like state in some cancer cell lines with wild 
type p53 without considerable effect on other cell types (Gorjala and Gary, 2010). This 
observation suggested that presence of wild type p53 alone was not sufficient to elicit a 
response to beryllium salt treatment. 
p53 protein plays a key role in the intracellular signaling network in sensing the 
DNA damage and regulating the cell cycle (Di Leonardo et al., 1994). p53 through p21 
mediates senescence in normal cells and is also responsible for senescence in cancer 
cells when exposed to drugs (Chang et al., 1999). p53 can be activated by various 
stress stimuli, DNA damage, short telomeres or activated oncogenes. The activated p53 
can induce expression of p21 which in turn can mediate cell cycle arresting actions (El-
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Deiry et al., 1993; Xiong et al., 1993). Studies have established that p21 can be 
expressed in both p53-dependent as well as p53-independent manner (Macleod et al., 
1995). Further it has been found that p21 can be up-regulated in p53 independent 
manner but p53 is required for p21 induction in situations where DNA damage is caused 
by radiation (El-Deiry et al., 1994; Michieli et al., 1994). 
Beryllium has been shown to introduce G1-S phase cell cycle block (Skilleter et 
al., 1983; Lehnert et al., 2001). Cyclin-dependent kinases (CDKs) are a family of protein 
kinases that are  periodically activated during cell cycle due to binding of proteins called 
cyclins. DNA damage or other genotoxic stress induces p21Waf1/Cip1 which binds to 
cyclin E-cdk2 complex. Binding of p21 to cyclin E-cdk2 complex results in competitive 
inhibition blocking S-phase entry to cells due to hypophosphorylation of pRb (Morgan, 
1996; Sherr and Roberts, 1995). Preliminary results from microarray data suggest that 
beryllium causes a decrease in cyclin E2 mRNA levels (unpublished data). 
A172 cells, a glioblastoma cell line, which are used for this study express wild 
type p53 sequence and have functional p53 protein (Ishii et al., 2006; Jia et al., 1997; 
Mirzayans et al., 2005). Beryllium is able to increase p53 and p21 in A172 cancer cells 
without DNA damage (Gorjala and Gary, 2010). In the present study we have 
investigated whether p21 induction and cell cycle arrest produced by beryllium is p53 
dependent. We have used three different “knock-down” methods, siRNA, shRNA and 
expression of E6 protein, to remove p53 protein or mRNA from cells. Short interfering 
RNA (siRNA) is an approximately 20 nucleotide long synthetic double stranded RNA 
molecule that can post-transcriptionally silence a gene. siRNA method has ready to use 
reagents and is the quickest method to knock down a specific gene. The protocol can be 
optimized to minimize off-target nonspecific effects but the knock down is transient and 
potent for short term experiments. On the other hand short hairpin RNA (shRNA) has a 
sequence inserted into viral vector plasmids. Expression of shRNA in target cells causes 
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silencing of target gene expression. shRNA provides an alternative to avoid working with 
RNA and can induce a stable expression. The disadvantages  of using shRNA include 
the need for time consuming cloning and the need for verification of insert. The third 
method used is E6 protein expressed by HPV that binds to the p53 protein and promotes 
its degradation in ATP dependent manner through ubiquitin-protease system (Scheffner 
et al., 1990). Each of the knock down methods removes either the mRNA transcript or 
functional protein from the cells. The result of each knock down method individually often 
is not completely effective in removing the gene product. On the other hand the “knock-
out” methods involve deletion of the target gene. By using three knock down methods in 
the same study we were able to complement the results from one method with the other 
and get a complete picture. 
MATERIALS AND METHODS 
Cell lines and reagents 
A172 (human glioblastoma) cells were from ATCC (Manassas, VA). Cells were 
grown in RPMI 1640 with Gluta-MAX and 25 mM HEPES (Invitrogen-Gibco) 
supplemented with 10% FBS (HyClone) and 1%  Antibiotic–Antimycotic (Invitrogen-
Gibco) at 37ºC in a 5% CO2 atmosphere. BeSO4. 4H2O used for dosing cells was from 
Fluka (a division of Sigma-Aldrich). 
A172-E6 cells are A172 cells transfected with pCMV-E6 expressing the human 
papillomavirus 16 E6 gene. A172-neo cells are A172 cells transfected with a similar 
plasmid without E6 (pCMV-neo) to serve as transfection control. Both A172-E6 and 
A172-neo are established and characterized as described earlier (Xu et al., 2005) and 
were kindly provided by Dr. J. Gregory Cairncross (University of Calgary, Calgary, 
Alberta, Canada). 
siRNA based p53 mRNA knockdown was done by using Validated Stealth RNAi 
DuoPak (Cat # 45-1492). Additional reagents used in the procedure were Lipofectamine 
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2000 (Cat # 11668-027) and OptiMEM reduced serum RPMI (Cat # 11058-02). Each of 
the Stealth RNAi molecules from Stealth RNAi DuoPak were used at a final 
concentration of 20 nM and Lipofectamine 2000 was used at 0.01 mg/mL. The reagents 
were diluted from stocks in OptiMEM. Each 100 mm plate recieved 2.5 mL of mixture for 
12 hours. The cells were then trypsinized and reseeded at required confluency and 
dosed with BeSO4. 
shRNA based p53 knock down was achieved by transducing A172 cells with p53 
shRNA (h) Lentiviral Particles (Cat#sc-29435-V) and transduction control cells were 
generated by using Control shRNA Lentiviral Particles (Cat# sc-108080) on A172 cells. 
Successfully transfected cells were selected by growing them in RPMI with puromycin 
followed by isolation of single cell clones.  
Cell count experiment 
50,000 cells  were seeded to 60mm plate for each dose. The cells were given 
change of media with BeSO4.4H2O at required concentrations. Cells were trypsinized by 
adding 0.5mL of trypsin EDTA followed by incubation at 37ºC  and 5% CO2 for 3 mins. 
The cells were resuspended in 2.5mL of RPMI. 100µL of cell suspension was used for 
cell counts. Remaining cell suspension was used to seed cells in to fresh 60mm plate at 
predetermined split volume to maintain subconfluency. Cell counts were taken using a 
Beckman Coulter Z1 counter. 
mRNA quantification by RT-PCR 
RNA from treated cells was isolated using RNeasy kit, cDNA was synthesized 
and Real Time-PCR was performed using QuantiTect SYBR Green PCR reagents from 
Qiagen. Primer pairs were, also from Qiagen - QuantiTect Primer Assay, QT00095431, 
QT00079247, QT00062090, QT000060235, QT00041986, QT01012284 for human 
beta-actin, human GAPDH, human p21(CDKN1A), human p53, human cyclin E1 and 
cyclin E2 respectively were used. Thermal cycling and data collection was performed  on 
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a Bio-Rad iCycler. iCycler software was used to determine PCR efficiency for each 
gene-specific primer set and to calculate the Starting Quantity (SQ) of gene-specific 
mRNA in each sample. Data was analyzed according to the method described earlier 
(Gorjala and Gary, 2010). 
Western blotting 
Cells ready for harvest were washed after RPMI was removed. Cell lysis was 
performed in plates by addition of 300µL of M-PER (Mammalian Protein Extraction 
Reagent, Pierce) supplemented with protease and phosphatase inhibitors. Total protein 
concentration was determined by using a bicinchoninic acid (BCA) assay (Pierce) and 
equal amount of total protein sample per well  was resolved on precast Bis-Tris Midi Gel 
and transferred to PVDF membrane. Immunoblotting was conducted using anti-p53 
mouse monoclonal (sc-126, clone DO-1), anti-p21 mouse monoclonal (sc-6246,clone F-
5), anti-actin goat polyclonal (sc-1615) antibodies from Santa Cruz Biotechnology, Inc, 
CA. Appropriate HRP-conjugated secondary antibodies were used and blots were 
developed with ECL Plus (GE Healthcare) imaged on a Typhoon Variable Mode Imager 
set to scan in fluorescence mode with a 457 nm laser and emission at 520 nm. Some of 
the blots were developed using Immun-Star™ WesternC™ Chemiluminescence Kit and 
images were taken using ChemiDoc XRS+ from Bio-Rad. 
Cell cycle analysis by flow cytometry 
After cell culture, the cells were fixed with 70% ethanol, treated with RNase, and 
stained with 50µg/ml propidium iodide (PI). Cellular DNA content was determined from 
PI fluorescence intensity using a Becton–Dickinson FACSCalibur flow cytometer and 
Flowjo data analysis software for cell cycle phase determination. 
DNA synthesis and total DNA content 
Cellular DNA synthesis was measured from the incorporation of 5-bromo-20-
deoxyuridine (BrdU). Cells were grown in the presence or absence of BeSO4 for 72 h. 
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Cells were allowed to grow for 61 h in 100mm plates. The cells were trypsinized, 
counted and re-seeded into 96-well plates at constant number into each well. Two 
identical 96-well plates were setup. The cells were allowed to and at the end of 72 hours 
BrdU label was added. Label incorporation was allowed for 3.5 hours and 96-well plate 
were processed and fluorescence was measured using a plate reader set to 340 nm 
excitation, 465 nm emission. 
RESULTS 
Three methods to knock down p53 mRNA or protein 
To generate A172 cell lines lacking p53 activity three different strategies were 
employed. 
Two different validated stealth siRNA sequences targeted to TP53 mRNA 
(accession number NM_000546) coding region between 252-1433 were used to induce 
knock down of p53 transcript. The resulting cells are referred to as KO1, KO2 and siRNA 
control treatment cells as KO control. We observed on western blot that the transfection 
target p53 protein is almost completely removed from the cells. The effect of siRNA 
though transient was effective in keeping the levels of p53 down even at the end of 
48hours (Fig 5.1a). 
As second approach we established sub-clones of A172 cells by infecting them 
with Lentiviral particles containing expression constructs encoding target-specific 19-
25nt shRNA to knockdown gene expression of p53. The sub-clones of A172 
constitutively express shRNA specific for p53. After transduction, cells expressing the 
constructs were selected under puromycin pressure. Single cell clones were isolated 
and propagated. Western blotting done on cell lysates of the clone used for this study 
(Fig 5.1b) show significantly reduced p53 protein compared to normal A172 cells. The 
established p53 knocked down clones are called as LVp53KO and transfection control 
clones as LVp53KOcontrol.  
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Figure 5-1 Downregulation of p53 protein siRNA and shRNA 
a. Two different validated stealth RNAi sequences (KO1 and KO2) were used to 
knock down p53 mRNA in A172 cell lines. Western blotting was used to evaluate 
levels of p53 and Actin protein in A172 normal, A172 KO1 and KO2 treated with 
0 and 10 µM BeSO4 for 24 and 48 hours. 
b. Reduced expression of p53 protein in A172 cells,LVp53KO. The p53 gene 
expression is knocked down by using p53 shRNA (h) Lentiviral Particles. 
Duplicate sample set is shown here.  
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Both the above methods work on mRNA to remove p53 transcripts from the cells. A third 
strategy used was expression of E6 protein from human papillomavirus 16. The E6 
protein expressed by HPV binds to the p53 protein and promotes its degradation in ATP 
dependent manner through ubiquitin-protease system (Scheffner et al., 1990; Vogelstein 
and Kinzler, 1992).  
Functional p53 makes A172 cells sensitive to growth inhibition by beryllium 
Beryllium was able to inhibit cell proliferation in the presence of functional p53 
protein. A172 cells that were expressing p53 i.e., A172, A172 KO control (Fig 5.2a) and 
A172, A172-neo in (Fig 5.2b) were very sensitive to 10 µM beryllium. Whereas cells with 
p53 knocked down showed tolerance to beryllium relative to cells with functional p53. 
Cumulative cell number of the three cell types A172 (functional p53), A172 
LVp53KOcontrol, A172 LVp53KO was almost same under 0µM beryllium (Fig 5.2c). In 
the presence of 10 µM beryllium the LVp53KO cells showed sustained increase in cell 
number over a period of 12 days but the cell types with functional p53 showed cytostatic 
response for up to 9 days followed by a decrease in cell number (Fig 5.2c).  
Beryllium induced accumulation of cells at G1-S phase and decrease in DNA 
synthesis  is p53 dependent 
BeSO4 causes G1-S phase block in A172 cells (Gorjala and Gary, 2010). Cell 
cycle analysis by flow cytometry confirmed this result in A172 and A172-neo cell lines. 
The percentage of cells in S phase at 0µM dose in A172 dropped from 15.1% +/- 1.1 to 
5.3 +/- 1.1 in 10 µM treated samples. Similarly the percentage of cells in S phase in 
A172-neo cell type changed from 9.4 +/- 1.1 to 1.2 +/- 0.2 between 0 and 10 µM doses. 
However the percentage of cells entering S-phase changed from 13.3% +/- 0.7 to 10.8 
+/- 0.4 with 10 µM beryllium treatment in A172-E6 cells which have low levels of 
functional p53 compared to A172 and A172-neo (Fig 5.3a). 
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Figure 5-2 Presence of functional p53 sensitizes cells to growth inhibition by beryllium 
a. A172 cells and p53 siRNA treated A172 cells (KO1, KO2, KO Control) were 
cultured RPMI with 0, 3, 10, 30, 100 µM  BeSO4 and counted at the end of 9 
days and shown here as percent of untreated cells (mean ± SD) of respective 
cell types. 
b. A172 cells, E6 expressing A172 cells and A172 Neo cells  were cultured in RPMI 
with  0, 10, 30, 100 µM  BeSO4 and counted at the end of 6 days. Counts are 
expressed as percent on untreated cell number (mean ± SD) of respective cell 
types. 
c. A172 cells with functional p53 (A172 and lentiviral control) or with p53 knocked 
down (Lentiviral p53 KO) were cultured in 0µM BeSO4 RPMI (left) and 10 µM 
BeSO4 (right)for 12 days. Cumulative cell number (mean ± SD) was determined 
every 3 days and cells were re-seeded to fresh plates to maintain sub 
confluency. 
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Figure 5-3 Beryllium induced accumulation of cells in G1-S phase and DNA synthesis 
block requires functional p53 protein 
 
The percentage of cells with p53 protein knocked down entering S-phase in the 
presence of BeSo4 is more compared to cells with functional p53. This observation also 
correlates with higher DNA synthesis activity in p53 knockdown cells compared to 
normal cells. 
A. A172 normal,A172-E6 and A172-neo cells were cultured in RPMI +/- 10 µM 
BeSO4 for 72hours. Propidium Iodide (PI) stain was used to measure DNA 
content using flowcytometry. Data is expressed as percentage of mean ± SD of 
total cells number of counted from three replicate samples.  
B. A172 cells were treated with siRNA to knock down p53 mRNA (KO1, KO2 and 
KO control serves as siRNA treatment control). A172 cells and siRNA treated 
A172 were cultured in RPMI with 0, 10, 30 µM BeSO4 for 72hours. Rate of DNA 
synthesis was analyzed by using BrdU incorporation assay. Values are 
expressed as mean ± SD of percent of A172 0µM BrdU fluorescence signal 
measured 
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DNA synthesis occurs during S phase of cell cycle. Beryllium can induce and 
maintain a reversible decrease of DNA synthesis (Gorjala and Gary, 2010). A172, KO1, 
KO2 and KO control cells were treated with10 µM beryllium for 72 hours. The rate of 
DNA synthesis was measured using incorporation of BrdU, a thymidine analog(Fig 5.3b). 
In normal A172 cells, the rate of DNA synthesis in 10 µM and 30µM BeSO4 cells 
decreased to 15% +/- 2 and 15% +/- 2 of control cells. At 10 µM dose of beryllium A172 
cells with p53 knocked down i.e., KO1 and KO2, showed a small decrease to 84% +/- 5 
and 86% +/- 5 relative to A172 cells at 0µM. 
Beryllium induced p21 increase is dependent on p53 protein 
p21waf/cip is an important cyclin-dependent kinase inhibitor that regulates the 
progress of cell cycle. p21 is known to function in both p53 dependent as well as 
independent manner. To evaluate significance of p53 in the cell cycle inhibition response 
of A712 cells to beryllium treatment, we have analyzed the mRNA and protein levels of 
p21. p21 is  a product of CDKN1A gene that is involved in cell cycle inhibition and a 
target for p53 transcription factor.  
A172, KO1, KO2 and KO control cells were cultured in RPMI with 0 and 10 µM 
BeSO4. mRNA levels for p53 and p21 were measured using quantitative RT PCR. The 
siRNA knock down of p53 gene expression was effective and is evident from p53 mRNA 
decrease to 46.0% and 33.6% of control in KO1 and KO2 respectively but no change 
seen in KO control cells (Fig 5.4). The p21 mRNA decreased to 55.4% and 34.9% of 
control in KO1 and KO2 cells treated with 10 µM BeSO4 but did not change in control 
and control KO cells. The A172 cells when treated with 10 µM beryllium showed 4 times 
increase in p21 mRNA. In A172 KO1 and KO2 the p21 levels increased modestly to 
122.99% and 91.84% of A172 control at 0µM treatments. Similar response was also 
observed in A172-E6 cells showing a small change compared to control cells in which 
p21 mRNA increased significantly (Fig 5.5). Although the expression of p53 mRNA in  
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Figure 5-4 BeSO4 up-regulation of  p21 in p53 dependent manner 
A172 cells were treated with siRNA to induce p53 mRNA knock down. The cells are then 
cultured in the presence of 0 or 10 µM BeSO4 for 48hours. mRNA levels of p53, p21, 
Actin and GAPDH in each sample were quantified using RT-PCR. Housekeeping genes 
Actin and GAPDH are expected to generate relatively constant amount of mRNA in 
control and treatment samples. mRNA quantities of all genes quantified were normalized 
relative to Actin mRNA and expressed as mean +/- SD of percent of A172 control 
values. 
  
53 
 
 
Figure 5-5 BeSO4 requires functional p53 for p21 mRNA increase 
A172, A172 E6 and A172 Neo cells were treated with 0 or 10 µM BeSO4 for 48 hours. 
mRNA levels of p21, Actin and GAPDH in each sample were quantified using RT-PCR. 
Actin mRNA values were used for  normalization. 
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A172 cells did not increase in response to beryllium treatment, the protein levels were 
higher (Fig 5.7).  
p53 and p21 protein levels were analyzed in cell types generated by the three 
different methods. The samples with p53 mRNA or protein knocked down showed less  
p53 protein compared to control and the corresponding samples also showed decreased 
p21 (Fig 5.7). 
Cyclin E1 and E2 levels are inversely related to functional p53 protein levels 
The basal level of cyclin E1 and cyclin E2 mRNA  in A172-E6 cells was higher 
than A172 control cells and showed no change of in response to 10 µM BeSO4 
treatment. On the other hand the A172 cells exposed to 10 µM beryllium the level of 
Cyclin E2 dropped to 8.9% of A172 controls while in A172-neo it decreased to 20.7% of 
A172 control. Similar trend was observed for cyclin E1 with A172 control cells 
expressing lower mRNA at 44.9% and neo cell type with 45.8% of A172 control when 
exposed to 10 µM beryllium. 
Looking at protein levels using western blot, we observed little cyclin E2 in A172 
cells. Therefore we investigated other cell types with increased cyclin E2 expression 
levels in order to verify that cyclin E2 changes could be measured in our system. MCF7 
cells expressed detectable levels of both cyclin E1 and E2. Helmbold et al (Helmbold et 
al., 2009) showed that untreated MCF7 cells express low levels of cyclin E1 and that 
cyclin E1 levels increase dramatically 7 days after ionizing radiation (20 Gy) treatment or 
doxorubicin (1 µM) treatment. A small increase of cyclin E1 protein was observed at the 
end of 2 days in ionizing radiation treated samples compared to control cells that 
received no drug treatment (Fig 5.8a). MCF cell line was used to ensure that we could 
detect both cyclin E1 and E2. Cyclin E1 was not detectable in A172 and young HFL-
1cells (Fig 5.8b). p53 knock down samples did not show any changes in cyclin E2 
protein even at 100 µM dose. However, A172 and LVp53KO control cells showed  
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Figure 5-6 Cyclin E1 and E2 mRNA levels are lower in cells with high p53 protein 
A172, A172 E6 and A172 Neo cells were treated with 0 or 10 µM BeSO4 for 48 
hours. mRNA levels of cell cycle regulating proteins Cyclin E1 (CCNE1), Cyclin E2 
(CCNE2) and housekeeping genes Actin, GAPDH in each sample were measured using 
RT-PCR. Data are expressed as percent of A172 control mean +/- SD 
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Figure 5.7 p21 protein expression is dependent on p53 protein 
a. Control cells were normal A172 , Neo were transfection control A172 cells 
and E6 were A172 cells expressing E6 protein that binds to p53 and 
degrades it.  
b. KO1 and KO2 represent two different siRNA sequences used to knock 
down p53. Normal A172 cells were represented by control and KO 
Control represents siRNA treatment controls 
c. LVp53 are A172 cells that have shRNA to silence p53 mRNA, transduced 
by using lentivirus. LV control are transduction controls and Control 
samples are from regular A172 cells. 
 
The cells were grown with 0 or 10 µM beryllium for 48 hours and protein 
levels were analyzed by western blotting. Same amount of protein was 
loaded to each lane. 
In all three types of p53 knocked down A172 cells p21 expression is 
dependent on functional p53 protein in the cell. 
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Fig 5.8 Effect of BeSO4 on Cyclin E2 protein expression is correlated with p53 status in 
A172 cell line 
a. To verify if changes in cyclin E could be detected  we used MCF7 cell line 
in an attempt to replicate results from (Helmbold et al., 2009). MCF7 cells 
were cultured with BeSO4 at 0, 10 and 100 µM  doses in addition to 
doxorubicin at 1 µM and ionizing radiation at 20Gy. Beryllium was 
maintained in cell culture during the entire time period. Cells were 
exposed to doxorubicin for 2 hours. The cells were harvested with MPER 
at the end of 2 and 7 days. A172 cells were cultured for a period of 4 days 
in 0,10 and 100 µM doses. A172 cells showed no detectable cyclin E1 but 
a decrease in cyclin E2 was observed at 100 µM  BeSO4 dose. 
b. A172 cells, LVp53KO and LVp53KO control cells , MCF7 and HFL-1 
young cells were cultured in the presence of BeSO4 for 4 days and total 
cell lysate was analyzed for cyclin E1 and E2 proteins. The A172 and 
LVp53KO control cells showed decrease of cyclin E2 at 100 µM  dose. 
HFL-1 cells showed no detectable cyclin E2 even at 10 µM dose. 
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decreased cyclin E1 at 100 µM and HFL-1 cells showed no detectable level of cylin E2 
at both 10 and 100 µM . 
DISCUSSION: 
Replicative DNA synthesis occurs during the S phase of cell cycle. BrdU data 
(Fig 5.3b) shows that there is decrease in DNA synthesis in cells with functional p53 
protein when treated with BeSO4. The decrease in DNA synthesis correlates with the G1 
block as evident from cell cycle analysis (Fig 5.3a). Beryllium can cause a cytostatic 
effect in cells with p53. The cells with p53 knocked down show some resistance to this 
effect of beryllium (Fig 5.2c). 
Be treatment causes phosphorylation of p53 at ser 15 (Gorjala and Gary, 2010). 
p53 stabilization is correlated with the phosporylation of Ser 15 (Shieh et al., 1997). In 
the presence of beryllium p53 binds to p21 promoter region (Coates et al., 2007). 
However, p21 can also be induced in a p53 independent manner (Michieli et al., 1994). 
Therefore we sought to determine whether p53 is necessary for p21 induction by 
berylliuim salt.  
Here we report that p21 induction by BeSO4 has been found to be p53 
dependent (Fig 5.4,5.5, 5.7). We have observed that there is no significant change in 
p53 mRNA but p53 protein is found to increase in response to beryllium treatment in 
dose dependent manner (Fig 5.4, 5.7).  
RNAi mediated removal of p53 mRNA from cells or inactivation of p53 by E6 
expression leads to a significant decrease of p21 gene expression (Fig 5.4, 5.5). Lower 
p21 mRNA in cells is reflected as lower p21 protein concentration in cells with p53 
knocked down. p53 is required for p21 induction in situations where DNA damage is 
caused by radiation (El-Deiry et al., 1994; Michieli et al., 1994). Beryllium induces p53 
and p21 without any DNA damage (Gorjala and Gary, 2010). The data presented here 
demonstrate that cells dosed with beryllium induce p21 in a p53 dependent manner. 
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Cyclin E2 is different from cyclin E (now called cyclin E1) in that it follows slightly 
different pattern of activity during cell cycle (Gudas et al., 1999; Lauper et al., 1998). 
Cyclin E2 mRNA levels peak at the G1-S transition phase. Normal human foreskin 
fibroblast cells were found to show increased cyclin E2 mRNA when p53 is degraded by 
E6 expression in these cell lines (Zariwala et al., 1998). In a microarray study of p53-
mediated transcriptional repression, CCNE2 was identified as one of the 111 genes that 
were down-regulated at least 2 fold after p53 over expression (Spurgers et al., 2006). 
Using microarray our group has found that CCNE2 is downregulated following beryllium 
treatment (unpublished data). Therefore, we sought to validate this finding using 
qualitative RT-PCR. If there is a decrease in expression of CCNE2 in response to 
beryllium we wanted to determine if it is p53-dependent beryllium response. 
We have found that A172 cells treated with BeSO4 with functional p53 show a 
significant decrease of cyclin E2 mRNA, to a lesser extent cyclin E1. The cells with p53 
inactivated show little change in cyclin E1 and E2 mRNA levels. The change of Cyclin 
E1 and E2 mRNA levels do not correlate with the corresponding protein expression. We 
found that cyclin E1 is not detectable in the total cell lysates of A172. A172 is glioma cell 
line and cyclin E1 is absent in human brain cells while cyclin E2 is observed in high 
levels(Zariwala et al., 1998). Using the same amount of total protein, beryllium resistant 
MCF7 cells expressed cyclin E1 protein that could be visualized using western blot. In 
A172 cells the changes in cyclin E2 protein in response to beryllium treatment could be 
seen after 4 day exposure at 10 and 100 µM (Fig 5.8a, 5.8b). In A172 cells The mRNA 
changes could be seen at the end of 48 hours upon exposure to 10 µM dose(Fig 5.6). 
Our experiments with A172 cells at shorter time points did not show observable changes 
in cyclin E2 protein levels (data not shown). The normal lung fibroblast cells HFL-1 
showed decrease of cyclin E2 protein at 10 µM dose for 4 day exposure (Fig 5.8b). 
BeSO4 is known to increase p53 protein in HFL-1 cells (Coates et al., 2007).  
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In the present study we have shown that p53 knock down in A172 is resulted in 
increased expression of cyclin E2 mRNA and protein. This correlates with E6 expressing 
cells entering S phase of cell cycle with higher DNA synthesis compared to cells normal 
A172 with functional p53 (Fig 5.3). All the evidence presents a possibility where BeSO4 
may be activating a branch of p53 network that inhibits cell proliferation via p21 and also 
simultaneously decreasing the level of cyclin E2 mRNA initially and protein at later 
stages to induce G1-S block. 
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CHAPTER 6  BERYLLIUM INDUCED CASPASE 3/7 DOES NOT CAUSE 
APOPTOSIS 
INTRODUCTION 
p53 is an important determinant in cellular response to stress. The apoptosis 
inducing function of p53 is under intensive study and its transcription dependent and 
independent pathways to induce apoptosis have been identified. The extrinsic pathway 
uses death receptors of tumor necrosis factor family of receptors (TNF-R) (Ashkenazi 
and Dixit, 1998). Activation of these receptors leads to cascade of events resulting in 
inducing activity of caspase 3, which in turn commits the cell to apoptosis. On the other 
hand p53 dependent intrinsic pathway is activated in the event of DNA damage and 
results in release of cytochrome c from mitochondria. cytochrome c forms a complex 
with apoptotic protease-activating factor 1 and procaspase 9 to activate other 
executioner caspases like caspase 3 (Gross et al., 1999; Li et al., 1998; Nicholson and 
Thornberry, 2003). 
The extrinsic pathway for apoptosis is activated by p53 dependent transcription 
of genes for Fas, DR5 and PERP. Among these Fas is an important member of TNF-R 
family of receptors that plays a crucial role in extrinsic pathway. p53 transcription factor 
binds to promoter of the Fas gene there by inducing its mRNA expression (Muller et al., 
1998). Unpublished data from microarray experiment on HFL-1 young cells treated with 
and without beryllium showed that some genes related to apoptosis are activated. FAS 
gene is the most up regulated in the list of genes in Table 6.1 (unpublished data, data 
not shown). One of the potential therapeutic strategies used in treatment of cancer 
involves using Fas and Fas ligand which are members of death receptor pathways. 
Here we present data that shows that caspase activation due to beryllium may 
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NCBI 
Reference 
Sequence 
Gene Definition 
NM_001065 TNFRSF1A tumor necrosis factor receptor 
superfamily, member 1A 
NM_001188 BAK1 BCL2-antagonist/killer 1 
NM_003842 TNFRSF10B tumor necrosis factor receptor 
superfamily, member 10b 
NM_005921 MAP3K1 mitogen-activated protein kinase kinase kinase 1 
NM_138578 BCL2L1 BCL2-like 1 
NM_033292 CASP1 
caspase 1, apoptosis-related 
cysteine peptidase (interleukin 
1, beta, convertase) 
NM_000043 FAS Fas (TNF receptor superfamily, 
member 6) 
 
not be leading to apoptosis. BrdU wash out experiment data shows that cells can revert 
back to active DNA synthesis state after the berylluim is removed from media. The data 
from XTT assays demonstrates that mitochondrial function is intact in the presence of 
beryllium. However, from the cell count data it is observed that there is decrease in cell 
number over long periods of exposure to higher concentration of beryllium. The 
Table  6-1 Apoptotic genes upregulated in beryllium treated HFL-1 cells 
List of genes up-regulated in HFL-1(Y) treated +/- 10µM beryllium in microarray analysis 
(unpublished microarray data from Gary Lab; gene expression changes have not yet 
been evaluated by RT-PCR for verification). 
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apoptosis signals initiated by death receptor pathways converge on the effector 
caspases like caspase 3 (Ashkenazi and Dixit, 1998; Schulze-Osthoff et al., 1998). 
Caspase 3 and 7 that are crucial for execution of apoptosis are activated in both 
extrinsic or receptor mediated and intrinsic or non-receptor mediated apoptotic pathway 
(Elmore S, 2007). The results documented in this chapter are from experiments setup in 
an attempt to verify if there is any apoptosis due to caspase 3/7 activity in the presence 
of beryllium. 
MATERIALS AND METHODS: 
Cell Culture 
HFL-1 (human lung fibroblasts), Wild type A172 (human glioblastoma)and RKO 
(human colon carcinoma) cells obtained from ATCC, were used for experiments. The 
cell lines were propagated RPMI1640 with GlutaMAX supplemented with 10% fetal 
bovine serum and 1% PSF. The cells were cultured in 100mm dishes at 37ºC with 5% 
CO2. 0.05% trypsin EDTA was used for trypsinizing the cells when splitting.KO1 and 
KO2 – p53 knock down was achieved using siRNA as described in chapter 5. 
Drug treatment: 
BeSO4.4H2O from Fluka was used to prepare a stock solution. Beryllium stock 
solution was diluted to required concentration in RPMI just before dosing.Staurosporine 
was from Calbiochem (Cat# 569396) and Sigma (Cat# S6942). Camptothecin from 
Sigma (Cat #C9911) was prepared according to instructions by dissolving 10mg in 1mL 
DMSO.Etoposide from Sigma (Prod. No. E1383) was prepared as a 50mM stock 
according to instructions. Q-VD-OPH (Cat#OPH 109) was purchased from Enzyme 
systems products Solon, Ohio. 
Caspase assay 
A predetermined number of cells are seeded into 96 well plate and cultured with 
or without drug. Activity of caspase 3/7 was measured with Caspase Glo 3/7 Assay (Cat 
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#G0890) and ApoTox-Glo™ Triplex Assay (Cat #G6321) from promega. When 384 well 
plate is used for assay the cells are cultured in 60mm plates with or without drug for the 
required length of time. The cells are then trypsinized and a specific volume from each 
plate is transferred to 384 well plates in triplicate. 
TUNEL assay 
Was performed with Fluorescein-12-dUTP based method optimized in house. 
The cells were analyzed using Flowcytometry. Detailed protocol adapted from original 
protocol by Heatwole VM (Heatwole, 1999) is given in appendix VI. 
DNA synthesis, Metabolism and Cell number 
Cells were grown in RPMI in the presence of required concentrations of BeSO4 
on 100mm plates. Each dose was setup in triplicate. After 64 hours cell were trypsinized 
and seeded into a 96well plate at the rate of 26000 cells per well. Cells from each plate 
were seeded in triplicates. Three identical plates were setup. Remaining cells were 
seeded into new 100mm plates for day 6 experiment. The cells in 96 well plate were 
allowed to attach for additional 8 hours. At the end of 72 hours cells were washed and 
BrdU incorporation assay was performed according to kit instructions from EMD 
Biosciences/Calbiochem. Similarly plates for XTT assay and CyQuant cell proliferation 
assay were also performed on the respective plates. 
Statistical Analysis 
Data sets with two dosage groups at each time point were analyzed by unpaired 
t-test, two tailed. Data sets with more than two groups were analyzed using one-way 
ANOVA with a post-hoc Bonferroni's multiple comparision test (P < 0.05 considered 
significant). 
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RESULTS 
Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in A172 and RKO 
Both A172 and RKO cell lines show increase in caspase 3/7 activity in response 
to treatment with apoptosis inducing drugs staurosporine, camptothecin and etoposide. 
The major difference in response between the cell lines is that RKO shows huge 
increase of caspase 3/7 at early time points of 12 and 24 hours whereas the increase in 
A172 cell line is at later time points of 24 and 48 hours (Fig 6.1). 
In A172 cells staurosporine was able to produce an increase caspase3/7 activity 
of 421% of control in first 12 hours which further increased with time reaching upto 
1029% of control by the end of 48 hours. Camptothecin and etoposide however showed 
caspase3/7 activity of approximately twice the control values at 24 hour time point which 
increased to 743% and 530% of control by 48 hour time point. 
RKO cells show an opposite pattern to A172 with highest activity of caspase 3/7 
in first 12 hours by staurosporine at 871% of control which decreased to 232% of control 
by 48 hour time point. Campothecin used at 10µM concentration induced caspase 3/7 
within first 12 hours and is maintained approximately at the same level even at the end 
of 48 hour time. Etoposide induced caspase 3/7 in RKO cells in a manner that is 
different from the other two drugs showing a very small increase of 150% of control in 
first 12 hours followed by a maximum increase upto 618% of control by 24 hours which 
is maintained at 537% by the end of 48 hour time point. 
Beryllium induces caspase 3/7 in A172 but not RKO 
Response of the two cell lines A172 and RKO to staurosporine, camptotheicn 
and etoposide is almost same as in Fig 6.1. RKO showed no change of caspase 3/7 
activity in response to beryllium treatment both at 24 and 48 hours (Fig 6.2). BeSO4 was 
able to induce a dose dependent increase of caspase 3/7 at 48hrs in A172 cells. A 10 
µM dose of beryllium was able to induce 303% of control increase of activity of caspase  
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Figure 6-1 Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in both 
A172 and RKO 
2500cells of A172 and 2000 cells of RKO were seeded into each well of a 96well plate. 
Each dose was seeded in triplicate. Media with staurosporin at 1µM, camptothecin at 
10µM and etoposide at 50µM was supplied at 48hrs, 24hrs and 12hrs before the assay 
time point. Caspase 3/7 activity was measured using Caspase Glo assay from promega. 
Apoptosis inducing drugs staurosporin, camptothecin and etoposide cause increase of 
caspase of approximately same amount in both A172 and RKO cell lines but at different 
time points. The data are presented as mean +/- Standard Deviation. Statistically 
significant differences are indicated with * P < 0.05. 
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Figure 6-2 Beryllium induces caspase in A172 but not RKO 
2500cells of A172 and 2000 cells of RKO were seeded into the wells of a 96well plate. Every 
dose was seeded in triplicate. Media +/- drug was supplied at 48hrs and 24hrs before the assay 
time point. The data are presented as mean +/- Standard Deviation. 
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3/7 which is comparable to effect of 50µM dose etoposide at 347% of control. 100 µM 
and 300 µM doses of beryllium increased activity of caspase3/7 to 832% and 1484% of 
control. 1 µM staurosporine and 10 µM camptothecin caused an increase of 915% and 
625% of control respectively. 
Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S) 
Both at 24 and 48hr time point beryllium was not able to induce caspase in HFL-
1(S)cells (Fig 6.3). In rapidly dividing A172 and HFl-1(Y) cells  beryllium induced 
caspase3/7 in dose dependent manner at 48hrs. The total amount of caspase3/7 
induced in A172 is higher compared to HFL-1(Y). 
Functional p53 is required for beryllium to induce caspase3/7 
From the results (Fig 6.4) we can see that KO1 cell type has abnormally high 
caspase3/7 activity. This may be caused by the duplex oligo used in siRNA treatment for 
p53 knock down. It should be noted that the morphology of KO1 cells was also abnormal 
compared to A172, KO1 or KO control. 
As seen in earlier experiments the A172 cells show dose dependent increase of 
caspase3/7 activity. The KO control cell type also shows similar pattern. The KO2 cell 
type with p53 knock down shows almost no increase of caspase3/7. At 300 µM dose, it 
can be seen that there is difference in activity of caspase3/7 between A172 control 
(587.5%), KO control (479.8%) and KO2 (265.6%).This data suggests a possibility that 
functional p53 may be required for beryllium based increase of caspase activity. 
Beryllium induced caspase3/7 may not cause cell death in A172 and HFL-1(Y) cells 
Q-VD-OPH is an anti-apoptotic drug that can inhibit activity of many different 
caspases including capase 3. The results (Fig 6.5) demonstrate that Q-VD-OPH at 50 
µM concentration was able to inhibit activation of caspase induced by beryllium even at 
a high dose of 100 µM. The response of both A172 and HFL-1(Y) cells is following the 
same pattern. 
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Figure 6-3 Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S) 
2500cells of A172 and 2000 cells of HFl-1(Y) at passage 14 were seeded into each well of a 
96well plate. HFL-1 (S) cells at passage 33, that are not dividing were seeded at 16,000 cells per 
well. Each cell line for each dose was seeded in triplicate. Media +/- drug was supplied at 48hrs 
and 24hrs before the assay time point. The results are plotted as percent of control on log scale 
to present the differences between cell lines clearly. The data are presented as mean +/- 
Standard Deviation. 
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Figure 6-4 Functional p53 is required for beryllium to induce caspase3/7  
A172 cells treated with siRNA to knock down p53, KO1 and KO2 along with KO control and 
regular A172 cells were cultured in 60mm plates with +/- beryllium. Each dose for each cell type 
setup in triplicates. At the end of 48hrs, 20µL of the cell suspension from these plates(including 
the floating cells) was seeded into 384well plate. Contents from each plate seeded to 3 wells. 
ApoTox-Glo™ Triplex Assay was used to generate this data. This kit combines caspase glo kit 
with a Live / Dead cell detection assay. This enables measuring of 3 parameters in each well. The 
caspase values were normalized with ratio of live cell to dead cells. All values expressed as 
percent of Control  at 0µM beryllium. Abnormally high caspase 3/7 in KO1 0µM may be caused 
by the duplex oligo used in siRNA treatment. Unlike KO2 and KO control. The data are presented 
as mean +/- Standard Deviation. 
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Figure 6-5 Beryllium induced caspase can be inhibited by QVDOPH 
 6.5a and b: 2000 cells of A172 and 2500 cells of HFL-1(Y) were seeded into each well 
of 96well plate. Two 96 well plates were setup for each cell line. The cells were dosed 
with  RPMI +/- beryllium and beryllium + Q-VD-OPH (50µM). At the end of 48hrs cy-
quant and caspase assay were performed on the respective plates. The data are 
presented as mean +/- Standard Deviation. 
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In the presence of beryllium alone or beryllium and Q-VD-OPH we can see that 
there is decrease of cell number with increasing concentration of beryllium. The cell 
number measurement was done using Cy-Quant assay. 
 Taken together these results show that the decrease in cell number in the 
presence of beryllium may not due by apoptosis caused by caspase3/7 activation. 
Beryllium induced caspase does not lead to Apoptosis 
Beryllium at 10 µM did not cause any labeling by TUNEL assay as compared to 
control cells which did not receive any drug treatment (Fig 6.6). At a higher concentration 
of 300 µM there is around 10% higher signal compared to control. On the other hand the 
positive controls DNAase I treated cells (39%), camptothecin (10 µM – 67% and 100 µM 
– 86%) and staurosporine (69%) treated cells show a very high percentage of cells 
undergoing apoptosis as detected by increase in signal. The difference in TUNEL 
positive signal between beryllium treated and positive control treatments indicate that 
beryllium may not be inducing apoptosis to the extent as expected by the caspase3/7 
activation. 
Beryllium induced inhibition of DNA synthesis is reversible 
In the presence of 10 µM BeSO4 by the end of 72 hours there is significant 
decrease of DNA synthesis as measured by BrdU incorporation assay (Fig 6.7A). For 
the same time point and dose, the activity of mitochondria (Fig 6.7B) or the total DNA 
content (Fig 6.7C) did not change comparably. However, when the cells are continued in 
culture without beryllium the DNA synthesis activity showed recovery reaching 50% of 
control treatment by the end of 6 days and by 9 days the recovery was almost 100% of 
control (Fig 6.7A). There is no change in mitochondrial activity and total DNA content at 
day 6 and 9 (Fig 6.7B, 6.7C). 
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Figure 6-6 Beryllium induced caspase does not lead to Apoptosis 
A172 cells were treated with 10µM and 100µM beryllium for 48hours, Camptothecin 10µM and 
100µM for 48 hours and staurosporine 0.2µM for 24 hours were processed according to TUNEL 
assay protocol for flowcyotmetry. The data are presented as mean +/- Standard Deviation. 
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Figure 6-7 Beryllium induced inhibition of DNA synthesis is reversible 
A172 cells were treated with 0µM, 1µM, 3µM and 10µM beryllium for 72hours as described in 
methods section and day 3 readings were taken for BrdU incorporation, XTT and CyQuant. The 
cells were cultured further in RPMI without beryllium and readings were taken on day 6 and day 
9. The data are presented as mean +/- Standard Deviation. 
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DISCUSSION 
The data in chapter 4 shows that beryllium may not be causing cell death. The 
microarray data showed increased expression of apoptosis related genes. Due to this 
the possibility of apoptosis had to be investigated. To use as positive controls we have 
selected 3 drugs (staurosporine, camptothecin and etoposide) that are known to induce 
apoptosis. 
The exact mechanism of action of staurosporine, a protein kinase inhibitor, is not 
clearly understood. But studies point to a possibility that it can induce apoptosis at early 
stages through caspase-dependent mechanism and at later stages can employ a 
separate signaling pathway that is caspase-independent (Belmokhtar et al., 2001; Zhang 
et al., 2004). Camptothecin forms a complex with DNA and topoisomerase I resulting in 
DNA damage. It is specifically potent in S phase cells (Hsiang et al., 1985; Hsiang et al., 
1989). Etoposide is a DNA topoisomerase II inhibitor and functions by blocking DNA 
topoisomerase resulting in DNA strand break. Etoposide requires p53 for its apoptosis 
inducing function (Grandela et al., 2007; Karpinich et al., 2002). The time points at which 
these drugs induce activity of caspase may be different from each other due to 
difference in mechanism of action. The same reason may also explain the difference in 
the time points of caspase induction between cell lines. However, the three drugs were 
able to induce caspase 3/7 activity in both the sensitive A172 and the resistant RKO cell 
line. The apoptosis inducing effect of DNA replication interfering drugs, camptothecin 
and etoposide, as measured by caspase3/7 activity is seen at earlier time point in RKO 
cells compared to A172. This may be due the shorter cell doubling time of RKO cell line. 
The standard apoptosis inducing drugs were able to induce caspase in RKO cell 
line within 24 hours, BeSO4 did not show comparable effect on this beryllium resistant 
cell line. The caspase 3/7 activity was dose dependent in A172 cell line and is seen at 
48 hour time point. The timing of caspase 3/7 activity induction is similar to camptothecin 
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and etoposide suggesting that beryllium may be following the similar pathway used by 
these two drugs. However it has to be noted that in chapter 4 it was demonstrated that 
there is no DNA damage as seen by phosphorylation of  γ-H2AX. The caspase 3/7 
activity measured in the presence of BeSO4 in HFL-1 young (Y) and senescent (S) cell 
lines (Fig 6.3) suggests that active cell division is required for BeSO4 to induce 
casase3/7 activity. Additionally the BrdU incorporation assay on A172 cells shows that 
beryllium induced inhibition of DNA synthesis is not permanent (Fig 6.7A). Also there is 
no decrease in metabolic activity of cells in the presence of beryllium as seen from the 
XTT data (Fig 6.7B). 
TNF receptor superfamily member, Fas gene is upregulated by beryllium dosing 
as seen in preliminary data from microarray experiment. Evidence from other studies 
that fas gene can be upregulated by p53 (Muller et al., 1998). Apoptosis initiated by 
death receptor through extrinsic pathway also results in activation of caspase 3/7. 
Caspase3/7 activity measured in p53 knocked down cells provides some evidence that 
functional p53 may be required for activation of caspase3/7, especially at higher doses 
of 100 and 300µM beryllium. In the siRNA system used for this experiment one of the 
duplex oligos used to generate KO cell type KO1 may be causing activation of caspase 
3/7.  
The distinct feature of apoptosis is that the initiation of caspase cascade results 
in DNA fragmentation. In any case if only caspase initiation is observed without any sign 
of other characteristic features of apoptosis like DNA fragmentation such a cell death 
cannot qualify as apoptosis (Takemura et al., 2001). The TdT-mediated dUTP Nick End 
Labeling assay called as TUNEL assay, labels the ends of the degrading DNA in 
apoptotic cells using the enzymatic activity of polymerase terminal deoxynucleotidyl 
transferase (TdT) (Gorczyca et al., 1992; Gorczyca et al., 1993). The flowcytometry 
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based TUNEL data shows that beryllium at 10 µM does not cause any labeling. The data 
suggests that DNA fragmentation is not taking place in the presence of beryllium. 
Recent discoveries show that there are caspase-independent mechanisms that 
can cause apoptosis. Discovery of XIAP based inhibition of caspase 3 showed that 
activation of caspase 3 does not necessarily always induce apoptosis (Deveraux et al., 
1999; Scott et al., 2005). Studies have shown that XIAP based caspase 3 inhibition 
protects the cell from CD95 (Fas/Apo-1) mediated apoptosis (Bratton et al., 2002). We 
have used a well-known pan caspase inhibitor Q-VD-OPH to verify if the reduction in cell 
number seen at higher doses of beryllium is due to cell death caused by caspase 
induction. Q-VD-OPH has antiapoptotic properties  and is not toxic to cells high 
concentration (Caserta et al., 2003). From the data (Fig 6.5 A, 6.5B) it is evident that 50 
µM Q-VD-OPH was able to effectively inhibit the activity of caspase 3/7 at all 
concentrations of beryllium used in the study. The cyquant assay data used to calculate 
cell numbers on a replicate plate setup in parallel shows that the Q-VD-OPH inhibition of 
caspase 3/7 is not able to rescue the cells from cell death at higher concentrations of 
beryllium (Fig 6.5C, 6.5D). 
The scope of this study is limited to check if the increase in caspase 3/7 is 
resulting in apoptosis of beryllium sensitive cell line. In this study we have checked an 
early and a late markers of apoptosis i.e., caspase 3/7 activity and DNA fragmentation. 
These markers give information concerned with nuclear and cytosolic compartments of 
the cell. To completely evaluate the effect of beryllium with respect to apoptosis further 
study is required using RT-PCR and western blotting techniques to evaluate the 
expression of mRNA and proteins of early markers like bcl-1, BAX, TRAIL. These 
proteins are concerned with changes in mitochondria. Flow cytometry based evaluation 
of membrane changes using Annexin V and mRNA, protein data related to Fas receptor 
activity will give a complete picture.   
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CHAPTER 7  SUMMARY AND FUTURE DIRECTIONS 
SUMMARY 
1. Beryllium salt can inhibit cell proliferation in susceptible cancer cell lines. 
2. BeSO4 causes phosphorylation of p53. This stabilizes p53 leading to its 
accumulation in the cell. 
3. Other changes induced by BeSO4 treatment include increase of p21, 
Senescence-associated beta-galactosidase activity. G1-S cell cycle block and 
decreased DNA synthesis are also observed. 
4. In spite of changes in intracellular activity that resembles DNA damage response 
pathway there no DNA damage caused by BeSO4. 
5. Increase of p21 and cell cycle arrest in response to BeSO4 treatment are p53 
dependent. 
6. p53 is required in sensitive cancer cells for regulating cyclin E2 expression in 
response to BeSO4 treatment. 
7. Caspase 3/7 activity was found to be increased in beryllium sensitive cancer cells 
treated with BeSO4. But there is no correlation between caspase 3/7 activity to number 
of cells undergoing apoptosis. 
FUTURE DIRECTION 
1. Survey of cancer cell lines in chapter 3 revealed that different cell lines have 
different levels of tolerance to BeSO4 dosing. ICP-MS data in chapter 4 shows that the 
uptake of beryllium by sensitive and resistant cell types is almost equal thus, suggesting 
that the amount of beryllium inside the cells may not be the reason for differences in 
sensitivity to BeSO4. We have also found that functional p53 is required for induction of 
cell proliferation arrest in response to BeSO4 treatment. The survey included wild type 
and mutant p53 expressing cell lines. No correlation was observed between p53 status 
and beryllium resistance. The mechanism by which some cell lines can resist beryllium 
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is not clear. A detailed survey which includes a wide range of cell types from different 
tissue sources may help in identification of the pattern. 
2. A nominal decrease in mRNA expression of cyclin E1 and E2 is observed in 
A172 cells by the end of 48 hours of BeSO4 treatment. Such a change is not seen in the 
corresponding protein levels by 48 hours (data not shown). However, cyclin E2 protein 
levels decreased by the end of 4 days. Cyclin E1 protein levels were below detection 
limit of the antibodies used in western blotting. Cyclin E1 and E2 protein expression 
begins at the same time during G1-S transition. The peak expression and degradation of 
cyclin E1 arrive early compared to cyclin E2 (Lauper et al., 1998). Studies have shown 
that ubiquitin dependent proteolysis ensures early degradation of cyclin E1 (Won K and 
Reed S., 1996). However, not much research has been done related to cyclin E2.  
 We have also observed that altered cyclin E2 mRNA levels in beryllium treated 
cells are dependent on p53. CCNE2 is one among the cell cycle regulatory genes that is 
identified as a possible target for miR-34 miRNAs. mir-34 family of miRNAs that are in 
turn regulated by p53 (He L et al ., 2007). The details of a possible pathway through 
which p53 dependent regulation of cyclin E2 operates are not yet clearly known. A 
detailed study to investigate the mechanism that regulates the activity of cyclin E2 
through p53 will be contribute to overall understanding of the cell cycle arresting effects 
of BeSO4. 
3. Preliminary data from microarray experiments showed that FAS gene is 
upregulated in response to BeSO4 treatment. It has been found that p53 can bind to Fas 
gene promoter (Munsch et al., 2000). In the present study we have shown that functional 
p53 is required for growth arresting effects of beryllium. An earlier study  published by 
our lab group has demonstrated that in response to BeSO4 treatment p53 functions like 
a transcription factor, binds to the promoter region and induces p21 mRNA expression 
(Coates SSA et al., 2007). Validation of microarray results related to FAS gene 
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upregulation, followed by gene expression studies using p53 knock out varieties of cell 
lines will allow us to test whether FAS gene expression in the presence of BeSO4 is also 
p53 dependent. We have also observed an increased caspase 3/7 activity in response to 
BeSO4 treatment. The pathway leading to increase in caspase 3/7 activity in BeSO4 
treated sensitive cell lines is not yet mapped. Since the protein encoded by FAS  gene 
plays an important role in extrinsic pathway for apoptosis further investigation into the 
FAS gene related results from microarray data will be a good starting point in elucidating 
the caspase 3/7 activation pathway. 
4. Increase of caspase3/7 did not induce apoptosis in BeSO4 treated samples. In 
this study, changes in levels of activated caspase3/7 have been verified using Caspase-
Glo 3/7 assay only. Additional assays comparing the total caspase 3 to the amount of 
activated caspase in the presence and absence of BeSO4 are required. These assays 
will help getting an accurate picture and also to validate  the results from Caspase-Glo 
3/7 Assay.  
 It may be possible that inhibitor of apoptosis proteins (IAP’s) are involved in 
protecting the cells form caspase 3/7 in the presence of BeSO4. Some studies have 
shown that in p53 mediated apoptosis, the increase of p53 protein correlates with 
decrease of XIAP, a potent member of IAP family (Mohapatra et al., 2005; Zou et al., 
2012). An investigation directed towards the activity of IAPs in BeSO4 treated samples 
may provide an answer to the failure of apoptosis in the presence of activated caspase 
3/7.  
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Appendix I Characterization of an alternative +/- p53 human glioma 
model system (U87MG) 
BACKGROUND 
A172, U87MG cell lines and their corresponding variants transfected to express 
E6 protein and transfection control sequence were obtained from Dr. Gregory 
Cairncross, University of Calgary, Alberta T2N 1N4, Canada (Xu et al., 2005). Both cell 
lines were tested for sensitivity to beryllium using cell count method. A172 cell line data 
is used in chapter 5. U87MG cell line data is documented here. 
EXPERIMENT 1 
Objective 
To check the sensitivity of U87MG, U87MG-E6 and U87MG-Neo cell lines’ to 
beryllium. 
Method 
The cells are exposed to selected range of beryllium concentrations at 0, 
10,30,100,300 micro molar range for a period of 9 days. The cell counts are taken at the 
end of 3rd, 6th, and 9th day. Cells were diluted and reseeded to maintain in sub-confluent 
state. 
The initial cell number to be seeded is 90,000 cells/plate. It is known from earlier 
experiments that U87MG cell line grows slow so higher cell number is seeded instead of 
regular 75000 cells/plate at 3ml per plate for this experiment. After the cells are allowed 
to attach for a period of 24 hours, the plates are shuffled, labeled with concentration fo 
beryllium and +/- beryllium RPMI is supplied to cells. One set of plates seeded for Day 0 
counts are trypsinized and counted to get the starting cell number. 
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Cell count and reseeding procedure 
Old media is removed and cells are washed with P.B.S one time. 
0.5 mL of trypsin EDTA is added to the cells and plate is incubated for 3 minutes  
at 37°C. 2.5 mL of RPMI is added to inactivate the trypsin and cells are suspended in 
RPMI. 100 µL of cell suspension is transferred into a coulter counter cup filled with 9.9 
mL of isotone. 
7 mL of RPMI with 8/7times the required concentration of BeSO4 is aliquoted to  
pre-labeled 15 mL tubes. After taking 100 µL for cell counts, 1 mL of the cell suspension 
is added to the respective 15 mL tubes with BeSO4 RPMI, this gives us 1:8 diluted cell 
suspension of which 3 mL was  seeded to new pre-labeled 60 mm dishes. 
The above procedure is followed for reseeding and counting cells on day 3,6 and 
9. On day 9 experiment is terminated. 
Result 
From the data obtained it can be seen clearly that U87MG-E6 cells are able to 
tolerate BeSO4 presence better compared to the control cell types. This result suggests 
that functional p53 may be required for the effects of beryllium to be seen (Fig 1). 
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Figure 1 U87MG Cal, Neo and E6 cell counts  
Over a period of 9 days U87MG-E6 cell type is able to withstand presence of beryllium compared 
to Control cell types. The abnormally high reading on day 9 for U87MG-E6 at 300µM 
concentration is an experimental error. The data are presented as mean +/- Standard Deviation. 
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EXPERIMENT 2 
Objective 
To verify the p53 dependence of p21 expression in response to beryllium in 
U87MG, U87MG-E6 and U87MG-Neo cell lines 
Method 
All the three cell lines are dosed with 0, 10µM and 100µM BeSO4 for 48hours 
and harvested using MPER with protease and phosphatase inhibitors. 
Result 
p21 expression is p53 dependent in U87MG cells and is dose dependent in 
response to BeSO4 treatment (Fig 2). 
 
Figure 2 U87MG Cal, Neo and E6 Western blots 
 Cal cells are regular U87MG, U87MG-E6 express E6 protein that binds to p53 protin making it 
inactive and U87MG-Neo are transfection control cells. 
 
EXPERIMENT 3 
Objective 
To verify p53 dependence of p21 gene expression in U87MG cells. 
Method 
U87MG, U87MG-E6 and U87MG Neo cells were treated with BeSO4 at 0,10 and 
30 µM BeSO4 and RNA extraction was done at the end of 48hours. 
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Result 
p21 mRNA expression is p53 dependent in U87MG cells and is dose dependent 
in response to beryllium treatment (Fig 3) 
 
Figure 3 U87MG Cal, Neo and E6 p21 gene expression RT PCR data 
Cal cells are regular U87MG, U87MG-E6 express E6 protein that binds to p53 protein making it 
inactive and U87MG-Neo are transfection control cells. mRNA quantification was done using real-
time PCR method. The data are presented as mean +/- Standard Deviation. 
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Appendix II Characterization of a spontaneously-arising Be-resistant 
clonal derivative of A172 
BACKGROUND 
IsoB11/17RS and IsoB11/9’RS cell types were generated from normal A172 cells 
by Dr. Ronald Gary. The procedure followed briefly is as follows. Normal A172 cells 
were grown in Be RPMI for long duration. The surviving cells were propagated resulting 
in A172 cells that have developed resistance to beryllium. The cell count experiment was 
done on IsoB11/17RS and IsoB11/9’RS cell lines along with normal A172 cells as 
controls for comparison. 
Objective 
To verify if IsoB11/9’RS to beryllium have developed resistance to higher 
concentrations of beryllium compared to A172 cells. 
Method 
The cells are to be exposed to 0,1,3,10,30,100,300, 1000, 3000,10,000 µM 
doses of BeSO4 for a period of 9 days. The cell counts are taken at 3rd day, 6th day and 
9th day. The cells are seeded in 60 mm dishes at 75000 cells/plate with each plate 
receiving 3 mL cell suspension. Day 3,6,9 cells counting and reseeding is done as 
described earlier. 
Result 
i) Iso B cell types of A172 are resistant than normal A172 cells (Fig 1) 
ii) Iso B 11/9’RS appeared to show more resistance to Be than Iso B11/17RS 
on day 3 but by Day 9 Iso B11/17 was more resistant (Fig 1) 
iii) Iso B11/17RS appeared to grow faster than Iso B11/9’ RS ( Fig 2). This is 
supported by the cell doubling time values and general observation during 
cell culture 
iv) Cytostatic concentration (Fig 3) 
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Cell type Cytostatic Conc 
Iso B 11/17RS 30µM 
Iso B 11/9’RS 30µM 
A172 (01/22/07) 10µM 
 
 
The lowest conc that is showing same cell number for 3,6,9 day counts is taken 
as cytostatic (Fig 3). However for all cell lines then next two conc’s also appear 
to maintain approximately same cell number. 
 
Cell type Doubling time 
Iso B 11/17RS 29 hrs 
Iso B 11/9’RS 35 hrs 
A172 (01/22/07) 28 hrs 
 
These values are calculated based on the time points at which the cell count procedure 
was started on Day 3,6, and 9 
  
Table 1 Cytostatic concentrations for Iso cell types 
Table 2 Cell doubling times 
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Figure 1 Iso cell types are resistant to beryllium compared to A172 
Day 3,6 and 9 cell count data is plotted as percent of control cells (0µM of respective cell 
lines)shows that the Iso cell types of A172 cell line were able to adapt to beryllium and 
have higher resistance compared to regular A172. The data are presented as mean +/- 
Standard Deviation. 
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Figure 2 Cell doubling time of Iso cell type is greater than A172 
The absolute cell counts with dilution factors of 8 for day 6 and 64 for day 9 incorporated 
into cell counts were plotted. Day 0 counts 48200, 31400 and 63466 for A172, IsoB 
11/17 RS and IsoB 11/9' RS respectively. By end of day 3 it can be seen that A172 cell 
were replicating faster compared to the Iso cell types. Among the Iso cell types Iso B 
11/17 RS were having lower cell doubling time. The data are presented as mean +/- 
Standard Deviation. 
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Figure 3 Cytostatic concentration of beryllium 
Dilution factor included total cell numbers are plotted against beryllium concentration for 
Day 3,6 and 9. For A172 the minimum concentration of beryllium that can stop cells from 
dividing is 10µM. The cytostatic concentration for Iso cell types is 30µM. The data are 
presented as mean +/- Standard Deviation. 
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Appendix III Evaluation of p53 and p21 status and response to 
beryllium treatment in BV cell lines 
BACKGROUND 
Four different cell lines were obtained from Dr. Bert Vogelstein’s lab. These are 
HCT116 cells (Human colon carcinoma cells), one of these being a p53 knock out and 
another is  p21 knock out along with two respective controls. 
EXPERIMENT 1 
Objective 
To check the sensitivity of all 4 cell lines to beryllium dose. 
Method 
The cells are exposed to 0, 1, 3, 10, 30, 100, 300, 1000 ,3000 ,10,000 µM doses 
of Be for a period of 6 days. The cell counts are taken at 3rd and 6th day. The experiment 
was set up in 60mm dishes. 75000 cells/plate at 3 mL  per plate were seeded on day -1. 
Cell count procedure 
Old media is removed and cells are washed with P.B.S one time. 
0.5 mL of trypsin EDTA is added to the cells and plate is incubated for 3 minutes  
at 37°C. 2.5 mL of RPMI is added to inactivate the trypsin and cells are resuspended in 
RPMI. 100 µL of cell suspension is transferred into a coulter counter cup filled with 9.9 
mL of isotone and used for getting cell counts. 
3rd day counts 
7 mL of RPMI with 8/7 times the required concentration BeSO4 for is prepared in 
the pre-labeled 15 mL tubes.  
100 µL of cell suspension is used for cell counts. 1ml of the cell suspension is 
added to the respective 15ml tubes with BeSO4 RPMI, giving 1:8 diluted cell suspension 
of which 3 ml will be seeded to new pre-labeled 60 mm dishes. 
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6th day counts 
Old RPMI is removed and cells are washed with P.B.S one time. 0.5mL trypsin is 
used for 3 minutes at 37ºC. Trypsin is inactivated and cells are suspended by using 2.5 
mL RPMI. 100 µLof cell suspension is transferred into9.9 mL of isoton for cell counting. 
Result 
Due abnormal counts obtained at various concentrations for each cell line no 
conclusions could be drawn from the data (Fig 1). 
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Figure 1 Cell count data for BV cells 
Cells were trypsinized and resuspended in RPMI with beryllium concentration 
calculated to compensate dilutions. 100µL of cell suspension was mixed with 9.9mL 
isoton solution. Coulter counter was used to get cell counts. Due to large standard 
deviation in cell numbers and abnormal counts obtained the data could not be used 
to arrive at any useful conclusions. The data are presented as mean +/- Standard 
Deviation. 
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EXPERIMENT 2 
Objective 
To identify p53, p21 knock outs and controls. 
Method 
1. Western blot 
2. Real time PCR 
1. Western Blot 
Cells for BV#2, #4, #17, #8 were setup in 100mm plates and harvested when the 
confluency reached 95% using RIPA extraction protocol. Extracted samples were mixed 
with 5x Lamelli sample buffer and boiled for 3 minutes. BCA assay was performed on 
remaining cell supernatant to determine total protein concentration. 
PAGE was performed using 9% acrylamide gel. Primary antibody treatment 
given using p21 and p53 antibodies over night. Corresponding secondary antibody 
treatment done and blots were developed using ECL+ reagent. Typhoon was used to 
scan the blot. 
Result 
Figure 2: p53 and p21 status in BV cell types 
BV#2 – p53 band absent - p53 knock out cell type; BV#4 – p21 band absent - 
p21 knock out cell type; Both BV#17 and BV#8 are expressing p53 and p21 protein 
and are control cell types. 
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2. Real time PCR 
Cells for each cell type, BV#2, #4, #17, #8, were cultured in 100mm plates and 
RNA was extracted from the cells. Reverse transcription was done to generate cDNA. 
cDNA diluted and used in Real Time PCR reactions to screen for p21 gene expression 
along with Actin and GAPDH. 
Result 
Extremly high concentration of BeSO4 at 1 mM was not able to induce p21 gene 
expression in p53 knocked down BV#2 cell type (Fig 3). At 100 µM BeSO4 dose the 
control cell line BV#8 did not show any response in the form of p21 mRNA expression. 
The results suggest that BV cell lines i.e., HCT116 are resistant to beryllium dosing and 
p21 expression in these cell is p53 dependent in response to beryllium treatment. 
Figure 3 p21 gene expression in p53 knock down BV cell line 
Cells were cultured in +/- Be RPMI for 48 hours at 0, 10, 30 and 1000µM 
concentrations. The starting quantity (SQ) of mRNA was measured using real time 
PCR techniques. Values are normalized with Actin and expressed as percent of 
control. The data are presented as mean +/- Standard Deviation. 
 
BV#2 cell line is p53 knock out variety and BV#8 is a control cell line. As 
seen from data the p21 gene is not expressed in BV#2 cell line even at very high 
concentraton of beryllium dose of 1mM. BV#8, with functional p53, required a very 
high dose to induce a response in the form of p21 gene expression increase. 
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Figure 4 p21 gene expression in p53 knock down BV cell line  
The experiment in Figure 3 is repeated with different concentrations of beryllium 
here. Exposure time is 48hours. The data shows that BV#8 ,the control cell line with 
wild type p53 gene, is able to resist effect of beryllium upto 100µM. The p53 gene 
expression at 300µM is doubled compared to control. On the other hand BV#2, the 
p53 knock out (p53KO) variety has no expression of p53 gene. The data are 
presented as mean +/- Standard Deviation. 
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Appendix IV Optimization of siRNA for p53 knock down and 
generating stable p53 knock down shRNA A172 clones 
EXPERIMENT 1 
BACKGROUND 
TP53 validated stealth RNAi (Cat No. 45-1492) was purchased from Invitrogen. 
The kit contains two Validated Stealth RNAi Duplex oligos. Cells treated with duplex 1 
and 2 are labeled as KO1 and KO2 respectively. 
Objective 
To test if the new TP53 validated stealth RNAi is able to induce efficient knock 
down of p53 expression. 
Method 
HFL-1 young cells at passage 16, hTERT HFL-1 and A172 cells were cultured in 
60mm plates and treated with validated stealth RNAi duplex oligos according to kit 
instructions. The cells were then treated with beryllium and western blotting method was 
used to verify presence of p53 protein.  
Result 
BLOCK-iT fluorescent Oligo was used to get an assessment of the transfection 
efficiency. The fluorescein-labeled duplex localized in nucleus  as expected (Fig 1). 
Validated stealth kit was able to induce p53 knock down efficiently in the three 
different cell types tested. The knock down was maintained over a period of 48 hours 
(Fig 2). 
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Figure 1 Nuclear localization of fluorescent tagged Oligos 
Left panels show the phase contrast images of the fluorescent field shown on right. 
Fluorescent image is taken with FITC filter having 494nm excitation and 519nm 
emission filters. 
hTERT HFL-1 (A) and A172 (B) were treated with BLOCK-iT and images taken at 
the end of 14 hours. 
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Figure 2 p53 protein screening in KO cells using western blot  
A172, HFL-1 young and hTERT HFL-1 cells were treated with validated stealth RNAi to 
induce p53 knock down and then cultured for another 24hours (Day1) and 48hours (Day 
2). The total protein concentration in HFL-1(Y) and hTERT HFL-1 samples was low so 
the samples used without normalization. But the Actin band shows that these samples 
were loaded at almost same total protein concentration. A172 samples were normalized 
using BCA assay. 
 
EXPERIMENT 2 
BACKGROUND 
The TP53validate steath RNAi kit was effective in inducing knock down of p53 in 
the different cell types tested. However, It was observed that cell morphology changed 
considerably after they receive Stealth RNAi treatment. According to the kit protocol the 
duplex sequences are required to be mixed with Lipofectamine 2000 and Optimem 
media. To improve the performance of kit by reducing damage to cells an experiment 
was designed to optimize the concentration of lipofectamine 2000 and duplex oligos. 
Objective 
To identify optimum concentration of duplex oligos and lipofecatmine 2000 that 
results in effective knockdown of p53 without causing changes in cell morphology. 
100 
Method 
A172 cells were treated with the following combinations of lipofectamine and 
duplex oligos. 100% refers to kit recommended concentration. 
100 % Oligo + 100% Lipofectamine 2000 
50 % Oligo + 50% Lipofectamine 2000 
100 % Oligo + 50% Lipofectamine 2000 
Cells were then harvested using MPER at the end of 48, 72 and 96 hours. The 
samples were normalized using BCA assay and western blotting was done to check for 
p53 levels. As a control sample extract from A172 cells treated with beryllium was used. 
Result 
The combination #2 having 50% concentration of oligo as well as lipofectamine 
was effective as 100% concentration upto 3 days. The cell death and morphology 
changes were lower than 100% concentration. At 4 days both 100% and 50% dosed 
cells showed recovery of p53 activity. It was decided to use 50% concentration for all 
future experiments with repeat dosing at the end of 72 hours for experiments that require 
p53 knock down to be maintained for longer periods. 
 
Figure 3 Optimization of Lipofectamine 2000 and Oligo concentrations 
100% refers to A172 cells treated with Kit recommended concentration (combination 1), 
50% lanes have cells treated with combination 2 at 50% of kit recommended 
concentrations, 50-100% lanes refer to samples from cells that were dosed with 50% 
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Lipofectamine 2000 and 100% Oligo, combination 3. Combination 3 samples were not 
run on gel due to limited number of wells on gel. Cells receiving 100% of lipofectamine 
2000 showed severe morphology changes and higher cell death. MPER lysed samples 
are resolved on PAGE and probed with p53 (DO-1) antibody 
 
EXPERIMENT 3 
BACKGROUND 
Integrating specific short hairpin RNA (shRNA) constructs into genomic DNA can 
induce targeted gene knock down. We have used p53 shRNA (h) Lentiviral Particles (sc-
29435-V) along with Control shRNA Lentiviral Particles (sc-108080) as negative control, 
from santa cruz biotechnology, inc,  to generate stably transfected A172, HFL-1 and 
hTERT HFL-1 cells. 
Method 
8000 cells of each cell type were suspended in 200µL of RPMI  and into 96 well 
plate. The cells were allowed to attach overnight. The lentiviral particles were diluted in 
RPMI with polybrene (Sigma Cat No. 107689) to get MOI of 0.5, 1, 2,4, 6 and 8. After an 
overnight incubation regular viral RPMI was replaced with regular RPMI. Puromycin  at 
750ng/mL in RPMI was used to select and propagate successfully transfected cells. 
Cells were tranfered to 60mm plates when wells in 96 well plate reached 90% 
confluency. Cloning cylinders (Sigma Cat No. C1059-1EA) were used to select single 
cell colonies for HFL-1 and A172 cells. The clones were further propogated and 
maintained under selection pressure using puromycin RPMI. hTERT HFL-1 cells used in 
this experiment were generated under puromycin selection. So the puromycin based 
selection in this experiment is not guaranteed to select for p53 knock down. So hTERT 
cells from high MOI wells of 96 well plate are saved. 
The clones were verified for p53 knockdown using western blotting. 
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Result 
The western experiment confirmed successful knock down of p53 protein in the 
clones selected. The transfected cells showed two bands for p53 with the lower band 
corresponding to the band seen in normal A172 sample. The lower molecular weight 
band is of lower intensity compared to control transfected cells. It has to be noted that 
single band was seen in other western blot experiments done with these A172 clones 
using a higher percentage gel.  
 
 
Figure 4 p53 protein screeing of A172 p53 shRNA knock-down clones 
Lentiviral treatment was able stably integrate shRNA to introduce p53 knockdown in the 
selected clones. hTERT HFL-1 cells were previously selected under puromycin and the 
cells may be a mixture of p53 knock down and p53 normal cells. A172 48 hour beryllium 
treated cell sample was used as a reference for p53 protein. 
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Appendix V Beryllium on the activity of GSK 3 beta 
BACKGROUND 
Work done by previous graduate student included study of the effect of beryllium 
on the activity of glycogen synthase kinase-3beta (GSK 3β). The western blot results 
presented in this chapter are an extension of her work. 
EXPERIMENT 1 
Objective 
To screen different cell lines for expression of GSK 3β and phosphor-Glycogen 
Synthase (pGS). 
Method 
A172, S91, PC12, RKO,MCF7 and HFL-1 cells were treated with beryllium 30and 
100µM, lithium  20mM,  1-Azakenpaullone - AKPL – 10µM and 5-Iodo-indirubin-3'-
monoxime – INDI - 20µM. MPER with protease and phosphatase inhibitors was used to 
harvest the cells at the end of 48hours. 
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Result 
 
Figure 1 Expression of total GSK, pGSK3β and pGS in 6 different cell lines 
Samples from all cell lines are not properly normalized. Both GSK-3α (~51 kDa) and 
GSK-3β (~47 kDa) proteins are seen in GSK-3 α/β panel. It appears that HFL-1 and S91 
cell lines may be having different levels of the enzyme. 
 
With respect to pGS and pGSK3β ser9 general observation is that both Synthetic 
inhibitors and Lithium were able to inhibit phosphorylation of GS compared to beryllium. 
Both Synthetic inhibitors and Lithium were able to induce phosphorylation of GSK3β at 
serine 9. The response of all cell lines to the different treatments is not same. Most of 
the HFL-1 samples and INDI samples were loaded to give maximum total protein load 
per well due to low protein concentration. 
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EXPERIMENT 2 
Objective 
To evaluate the influence of beryllium on the activity of GSK 3β as compared to 
Lithium and synthetic inhibitors.  
Method 
Phosphorylation of Glycogen Synthase and Tau, the substrates of GSK 3beta, 
will be used as measure of increase or decrease of the GSK 3β enzyme activity. 
A172, HFL-1 Young cells at passage 19 and PC12 were treated with Beryllium - 
10,30 and 100µM, Lithium – 10, 20, 30mM, 1-Azakenpaullone - AKPL – 10µM, 
Alsterpaullone - ALPL – 10µM. Cells were harvested using MPER with protease and 
phosphatase inhibitors at the end of 24 and 48 hours. 
1-Azakenpaullone and Alsterpaullone are synthetic inhibitors of GSK 3β (Leost et 
al., 2000). 
The samples were probed for pGS, Tau, pTau and actin. 
Result 
Images obtained from western blotting were faint and not clean thus making 
band identification difficult. The images below are labeled for sample lanes but not for 
specific bands of the proteins. 
The molecular weight marker shown for reference is for 4-12% gels as provided 
by manufacturer but the gels used for the experiment are 10% gels. 
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Figure 2 Tau(C-17) protein expression in A172, HFL-1 and PC12 
A172, HFL-1 and PC12 cells were treated with beryllium, Lithium and synthetic inhibitors 
as described in methods. The MPER extract of these cells was normalized using BCA 
assay. Protein samples are resolved using PAGE and  probed with Tau(C-17) antibody. 
A172 and HFL-1 blots have almost no bands. May be due to low protein conc combined 
with much lower levels of Tau in these cell lines. PC12 samples show some faint bands. 
The duplicate set of samples for PC12 were also run on gel and also pTau  levels were 
probed in PC12 samples only (Figure 2). The expected molecular weight for Tau(C-17) 
is 46-80 kDa. 
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Figure 3 pTau (Ser 396) in PC12 cells 
The duplicate set of samples from PC12 in figure 1 are probed with Tau(C-17) antibody. 
2 and 3 are blots for PC12 replicate set of samples probed for pTau (Ser 396). The 
expected molecular weight for pTau (Ser 396) is 45-68 kDa. 
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Figure 4 Actin levels to check total protein normalization 
Actin reprobe on phospho GS blot shows that some of the samples have very low 
protein. It indicates inefficient transfer or problem with primary antibody treatment. 
Molecular weight of Actin is approximately 43 kDa 
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Appendix VI TUNEL assay protocol 
Reagent List 
Equilibration buffer: Dilute 5x Terminal Transferase buffer.  
TdT: 30U/uL from TERMINAL DEOXYNUCLEOTIDE 1500U Promega 
Cat#M1875 
Required at 30U per reaction according to protocol 
PBS from HyClone Cat# ATH 32652  
2x SSC: Dilute the 20x SSC solution left over from promega kit in DI water. 
4% paraformaldehyde: prepared from paraformadehyde solid (Sigma P6148). 
Weigh 1.6g into 35mL P.B.S. Heat solution on hot plate set to 1 or 2. Use thermometer 
to monitor temperature at 65ºC. Use magnetic stirrer to stir the solution. Cover the 
beaker with aluminum foil to avoid splatter. When the solution turns clear stop stirring 
and allow cooling. Carefully measure the volume of solution remaining in the beaker and 
make up volume to 40mL. Store in 50mL tube at 4ºC. 4% paraformaldehyde is diluted to 
required concentration in P.B.S. 
0.2% Triton X100:  Sigma Cat# T9284 - Mix 80uL + 40mL P.B.S 
70% ethanol: 95% Denatured Ethanol (Cat# BDH1158-4) is diluted to 70% by 
mixing 29.4mL of alcohol with 10.5mL of P.B.S. 
DNase I : From Biolabs cat# M0303S. Stock concentration is 2000U/mL. Diluted 
in DNase I buffer to 1U/reaction 
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Nucleotide mix 
  
Required 
Conc 
Stock 
Conc  
Fluorescein-12-dUTP 50uM 1mM 
Fisher Scientific Cat No.: 
FERR0101 
dATP 100uM 1mM 
TQAC131- omega Bio-tek - 
VWR 
Secondary stock diluted to 
1mM from 100mM stock in 
Tris-Hcl 10mM pH7.6 
Tris-HCl pH 7.6 10mM 10mM  
 
TdT labeling mix 
  Stock Required for 1 Rxn 
Equilibration buffer 5x 
Terminal Transferase Buffer 
Promega Cat#M1893 
Dilute to half with DI water to get 
2.5x, use 100uL per reaction  
Nucleotide mix 
Use mix 
prepared 
above   10uL for each reaction 
TdT enzyme 30U/uL 
TERMINAL DEOXYNUCLEOTIDY 
1500U Promega Cat#M1875 
Use 1uL for each reaction 
   
 
Procedure 
Fixing cells 
1. Cells grown in tissue culture plates are trypsinized  by exposing cells to 0.05% 
trypsin for 3 minutes at 37ºC followed by deactivating with used RPMI collected 
into a pre-labelled tubes before adding trypsin. The cell suspension was 
collected into a prelabelled 15mL tubes.  
5. The cell suspension is centrifuged at 300xg, 4ºC for 6minutes. 
6. Supernatant is removed and cell pellet is gently dispersed by tapping the tube. 
7. Cells are washed twice in P.B.S. 
8. P.B.S is removed and tube is tapped gently to disperse the cells. 
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9. 1mL of 1% paraformaldehyde is added to the cells and incubate on ice for 
20minutes. 
10. Paraformaldehyde is removed by centrifuging cells at 300xg, 4ºC fror 5 minutes. 
11. P.B.S wash is given to cells twice 
12. After removing P.B.S, 70% cold ethanol is added to cells. 
13. The cells are stored at 4ºC till they are processed by TUNEL assay. 
TUNEL assay 
14. Remove ethanol form samples by centrifuging and wash the cells twice with 
P.B.S. 
15. Start processing DNase samples first. 
16. Equilibrate cells in equilibration buffer for 10minutes. 
17. Remove buffer by centrifuging cells at 300xg, 4ºC for 5 minutes. 
18. Add DNase I enzyme and incubate at room temperature for 10 minutes. 
19. Remove DNase I enzyme by centrifuging at 300xg, 4ºC for 5 minutes and wash 
cells with P.B.S one time. 
20. Prepare nucleotide mix and TdT labeling mix as required for the number of 
samples. 
21. To all samples add equilibration buffer and leave at room temperature for 
10minutes. 
22. Centrifuge and remove excess buffer. 
23. Add 100µL of TdT mix to each tube and incubate at 37ºC for 1 hour 45 minutes. 
24. Add 500µL of 10mM EDTA to stop the reaction. 
25. Centrifuge at 300xg for 10 minutes. 
26. Wash cells with P.B.S twice and remove excess P.B.S by centrifuging at 300xg 
for 10minutes. 
27. Resuspend cells in 100µL P.B.S and transfer the cells into flowcytometry tube. 
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28. Save the tubes on ice and process using flowcytometer set to read FITC label. 
 
** It was observed that FITC label can interfere with PI stain readings. It is 
preferable to prepare a parallel set of samples for DNA content analysis instead of using 
FITC cells to double label with PI stain.  
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